Page: 1
Protocol  Number: CA209800
IND Number: [ADDRESS_229524]- 2016
Revised Date 02-Aug- 2017
Clinical Protocol CA209800
Phase II, Rando mized, Study  of Mul tiple Administration Regimens for Nivo lumab plus 
Ipi[INVESTIGATOR_193154]: 02
Medical Monitor
Anila Qureshi, MD, MPH
Bristol -Myers Squibb Research and Development
This document is the confidential and proprietary information of Bristol -Myers Squibb 
Company and its global affiliates (BMS). By [CONTACT_52212], you agree to keep it 
confidential and to use and disclose it solely for the purpose of assessing whether your 
organ ization will participate in and/or the performance of the proposed BMS sponsored 
study. Any permitted disclosures will be made only on a confidential "need to know" basis 
within your organization or to your independent ethics committee(s). Any other use, copying, 
disclosure or dissemination of this information is strictly prohibited unless expressly 
authorized in writing by [CONTACT_20444]. Any supplemental information ( e.g., amendments) that may 
be added to this document is also confidential and proprietary to BMS and must be kept in 
confidence in the same manner as the contents of this document. Any person who receives 
this document without due authorization from BMS is requested to return it to BMS or 
promptly destroy it. All other rights reserved. References to BMS in this protocol may apply 
3.0
Approved
930107718
3.0
v

Clinical Protocol CA209800
BMS -936558 nivolumab
Revised Protocol No.: 0 2
Date: 02-Aug -[ADDRESS_229525] Research 
Organization (CRO).
Replace all previous versio n(s) of the protocol with this revised protocol a nd please provide a copy 
of this revised protocol  to all study  personnel under your supervisio n, and archive the previous 
versio ns.
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
Revised Protocol No.: 0 2
Date: 02-Aug -2017 3DOCUMENT HISTORY
Document Date of Issue Summary of Change
Revised Protocol 02 02-Aug -2017Adding clarifications to the protocol 
Correcting inconsistencies and text that was 
erroneously deleted in the Revised Protocol 01
Revised Protocol 01 18-Jan-2017 Incorpo rates Amendment 01
Amendment 01 18-Jan-2017Incorpo rate additional safety parameters and 
clarificatio ns as per the FDA guidance following the 
submission of IN D132265
Clarify  inconsistencies in the original protocol as per 
the review of local Ethical Committees
Correct typo errors on the original protocol
Administrative Letter 
0116-Nov -2016Delete one of the eligibility criteria in the protocol synopsis 
(and align it with the text in the eligibility criteria section of 
the protocol body ) that was erroneously included in the 
original protocol 
Original Protocol 25-Oct-2016 Not Applicable
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
 
Revised Protocol 02 will be applicable to all pat ients.
SUMMARY OF KEY CHANG ES FOR REVISED PROTO COL 02
Section Number & Title Description of Change Brief Rationale
Synopsis Exclusion Criteria 1 modified Ensure consistency with protocol body 
language
Section 2: Schedule of 
ActivitiesTiming for Vital Signs added; 
Timing for MDSC 
highlighted;
Duplicate Statements on Follow -
Up Assessments deletedThere was an inconsistency across the 
Schedule of Activities with regards to the 
timing of those assessments.
Section 4Objectives and 
Endpoints , Section 10.3.2, 
Safety AnalysesTiming of Primary Endpoint 
corrected to completion of Part 1 .Primary  Endpoint Analysis adjusted as
Primary  Endpoint is related to safety of the 
combinatio n dosing .
Section 7.4.3, Dose 
DiscontinuationAdded Grade 3 “diarrhea, colitis, 
neurologic toxicity” as reasons for 
dose discontinuationText erroneously deleted from revised 
Protocol [ADDRESS_229526] not been summarized
Revised Protocol No.: 02
Date: 02-Aug-2017 4
3.0
Approved
930107718
3.0
v

TABLE OF CONTENTS 
TITLE PAGE ................................................................................................................ 
DOCUMENT HISTORY .............................................................................................. 
 
SUMMARY OF KEY CHANGES FOR REVISED PROTOCOL 02 ......................... TABLE OF CONTENTS .............................................................................................. 1 SYNOPSIS ................................................................................................................. 2 SCHEDULE OF ACTIVITIES.................................................................................. 3 INTRODUCTION ..................................................................................................... 
3.1 Study Rationale ................................................................................................. 
3.1.1 Research Hypothesis ................................................................................ 
3.2 Background ....................................................................................................... 
3.2.1 Nivolumab Mechanism of Action ............................................................. 3.2.2 Ipi[INVESTIGATOR_102261] ............................................................ 3.2.3 Nivolumab Combined with Ipi[INVESTIGATOR_125] ................................................... 3.2.4 Programmed Death Receptor-1 (PD-1) and Nivolumab ......................... 3.2.5 Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) and Ipi[INVESTIGATOR_125] ............... 
3.2.[ADDRESS_229527] Treatments ............. 3.2.8 Nivolumab in Renal Cell Carcinoma ....................................................... 3.2.9 Ipi[INVESTIGATOR_114532] ...................................................... 3.2.10 Nivolumab Combined with Ipi[INVESTIGATOR_114532] ........ 
3.3 Benefit/Risk Assessment .................................................................................. 
4 OBJECTIVES AND ENDPOINTS ........................................................................... 5 STUDY DESIGN....................................................................................................... 
5.1 Overall Design .................................................................................................. 
5.1.1 Data Monitoring Committee and Other External Committees ................ 
5.2 Number of Participants ..................................................................................... 5.3 End of Study Definition .................................................................................... 5.4 Scientific Rationale for Study Design............................................................... 5.5 Justification for Dose ........................................................................................ 
5.5.1 Rationale for Nivolumab combined with Ipi[INVESTIGATOR_193155] .. 5.5.2 Rationale for Fixed Ratio Combination Dosing ...................................... 5.5.3 Rationale for Flat Dose 480 mg Nivolumab every 4 Weeks During 
Maintenance Phase ..................................................................................... 
5.5.4 Rationale for 2-arm Design ..................................................................... 5.5.5 Rationale for Choice of Adverse Events by [CONTACT_193197] (Broad Scope) as a Primary Endpoint ............................... 
6 STUDY POPULATION ............................................................................................ 
6.1 Inclusion Criteria .............................................................................................. 6.2 Exclusion Criteria ............................................................................................. 6.3 Lifestyle Restrictions ........................................................................................ 6.4 Screen Failures .................................................................................................. 
6.4.1 Retesting During Screening or Lead-In Period ....................................... 
7 TREATMENT ........................................................................................................... 1
3
4
4
5
8
16
25
25
25
25
25
26
26
29
29
29
30
31
31
32
33
3436
36
37
37
38
38
38
38
38
39
39
40
41
41
43
45
45
45
45Clinical Protocol
BMS-936558CA209800
nivolumab
Revised Protocol No.: 02Date: 02-Aug-2017 5
3.0
Approved
930107718
3.0
v

7.1 Treatments Administered .................................................................................. 
7.1.1 Part 1 Study Treatment Administration ................................................... 
7.1.2 Part 2 Study Treatment Administration ................................................... 7.1.3 Selection and Timing of Dose .................................................................. 
7.2 Method of Treatment Assignment .................................................................... 7.3 Blinding............................................................................................................. 7.4 Dosage Modification ......................................................................................... 
7.4.1 Dose Delay Criteria ................................................................................. 7.4.2 Criteria to Resume Treatment .................................................................. 7.4.3 Dose Discontinuation............................................................................... 7.4.4 Management Algorithms for Immuno-Oncology Agents ......................... 7.4.5 Treatment of Related Infusion Reactions ................................................. 
7.5 Preparation/Handling/Storage/Accountability .................................................. 
7.5.1 Retained Samples for Bioavailability / Bioequivalence ........................... 
7.6 Treatment Compliance ...................................................................................... 7.7 Concomitant Therapy........................................................................................ 
7.7.1 Prohibited and/or Restricted Treatments................................................. 7.7.[ADDRESS_229528] Result Abnormalities ..................................................... 9.2.7 Potential Drug Induced Liver Injury (DILI) ............................................ 9.2.8 Other Safety Considerations .................................................................... 
9.3 Overdose ........................................................................................................... 9.4 Safety ................................................................................................................ 
9.4.1 Physical Examinations ............................................................................. 9.4.2 Vital signs................................................................................................. 9.4.3 Clinical Safety Laboratory Assessments .................................................. 9.4.4 Imaging Safety Assessment ...................................................................... 
9.5 Pharmacokinetic ................................................................................................ 48
48
49
49
52
52
52
52
53
53
54
55
56
57
57
57
57
57
58
58
58
58
59
59
60
61
61
6162
63
63
64
64
65
65
65
66
66
66
67
67
67
67
67
68
68Clinical Protocol
BMS-936558CA209800
nivolumab
Revised Protocol No.: 02Date: 02-Aug-2017 6
3.0
Approved
930107718
3.0
v
9.6 Pharmacodynamics ........................................................................................... 
9.7 Pharmacogenomics ........................................................................................... 
 
 
 
 
 
 
 
9.9 Medical Resource Utilization and Health Economics ...................................... 
10 STATISTICAL CONSIDERATIONS .................................................................... 
10.1 Sample Size Determination ............................................................................. 10.2 Populations for Analyses ................................................................................ 10.3 Statistical Analyses ......................................................................................... 
10.3.1 Efficacy Analyses ................................................................................... 10.3.2 Safety Analyses....................................................................................... 
[IP_ADDRESS] Pharmacokinetic Analyses as a Secondary Endpoint ................... [IP_ADDRESS] Other Pharmacokinetic Analyses .................................................. 
 
[IP_ADDRESS] Outcomes Research Analyses ....................................................... [IP_ADDRESS] Other Analyses .............................................................................. [IP_ADDRESS] Interim Analyses............................................................................ 
11 REFERENCES ........................................................................................................ 12 APPENDICES ......................................................................................................... APPENDIX 1 ABBREVIATIONS AND TRADEMARKS ........................................ APPENDIX 2 STUDY GOVERANCE CONSIDERATIONS .................................... 
APPENDIX 3 ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS: 
DEFINITIONS AND PROCEDURES FOR RECORDING, EVALUATING, 
FOLLOW UP AND REPORTING ......................................................................... 
APPENDIX [ADDRESS_229529] 1.1 GUIDELINES .................................................................. APPENDIX 6 INTERNATIONAL METASTATIC RCC DATABASE 
CONSORTIUM (IMDC) PROGNOSTIC CRITERIA .......................................... 
APPENDIX 7 PERFORMANCE STATUS SCALES ................................................. APPENDIX 8 MANAGEMENT ALGORITHMS FOR IMMUNO-ONCOLOGY 
AGENTS ................................................................................................................. 71
71
71
71
72
72
72
72
73
73
74
74
75
76
76
78
82
82
82
83
83
83
84
87
88
93
102
106
110
118
119
120Clinical Protocol
BMS-936558CA209800
nivolumab
Revised Protocol No.: 02Date: 02-Aug-2017 7
3.0
Approved
930107718
3.0
v

Clinical Protocol CA209800
BMS -936558 nivolumab
1 SYNOPSIS
Protocol Title: Phase II, Randomized, Study of Multiple Administration Regimens for 
Nivolumab plus Ipi[INVESTIGATOR_193156] s with Renal Cell Carcinoma
Study Phase: Phase II
 
 
 
 
 
Study Population:
The study  population for this trial will include adult participant s (≥18 years) with histological 
confirmat ion of RCC with a clear -cell co mponent .
Key Inclusion Criteria: 
Histological confi rmation of RCC with a clear -cell com ponent
Advanced (not amenable to curative surgery  or radiation therapy ) or metastatic (AJCC Stage 
IV) RCC
No pri or sy stemic therapy  for RCC wi th the following except ion:
oOne prior adjuvant or neoadj uvant therapy  for completely resectable RCC if such 
therapy  did not include a checkpo int inhibitor and if recurrence occurred at least 
6months after the last dose of adjuvant or neoadjuvant therapy.
Karnofsky Performance Status (KPS) of at least 70%
Measurable disease as per RECIST 1.1 (invest igator assessed)
Tumor tissue (form alin-fixed paraffin- embedded (FFPE) archival or recent acquisit ion) must 
be received by [CONTACT_193198] (block or unstained slides) in order to randomize a participant
to study  treatm ent. (Note: Fine Needle Aspi[INVESTIGATOR_1516] [FNA] and bone metastases samples are not 
acceptable for submissio n).
Parti cipantswith favorable, intermediate and poor risk c ategori es will be eligible for the study.
oTo be eligible for the Intermediate -Risk cohort one or two of the fo llowing prognostic 
factors as per International Metastatic RCC Database Consortium (IMDC) risk factors 
include :
a) KPS equal to 70%
b) Less tha n 1 y ear from diagnosis to randomizat ion
c) Hem oglobin less than the LLN
d) Corrected calcium concentration greater than 10 mg/dL
Revised Protocol No.: 02
Date: 02-Aug-2017 8
3.0
Approved
930107718
3.0
v

Clinical Protocol CA209800
BMS -936558 nivolumab
e) Absolute neutrophil count greater than the ULN
f) Platelet coun t greater than the ULN
oIf more than two factors are present they  will be eligible for Poor -Risk cohor t.If none 
of the above factors are present, participant s are only eligible for the Favorable -Risk 
cohort. 
Key Exclusion:
Active brain metastases or leptomeningeal metastases . Baseline imaging of the brain is 
requi red wi thin 28 days pri or to randomizat ion.
Prior treatm ent with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA -4 
antibody , or any other antibody  or drug specifically targeting T-cell co-stimulat ion or 
checkpoint pathways.
Any act iveor recent history  of a known or suspected autoimmune disease or recent history  of 
a syndro me that required systemic corticosteroi ds (> 10 mg daily prednisone equivalent) or 
immunosuppressive medicat ions except for syndromes which woul d not be expected to recur 
in the absence of an external trigger. Participant s with vitiligo or type I diabetes mellitus or 
residual hypothy roidism due to autoimmune thyroidi tis only requi ring horm one replacement 
are permitted to enroll.
Any condi tion requi ring systemic treatm ent with corticosteroi ds (> 10 mg daily  prednisone 
equivalents) or other immunosuppressive medicatio ns within [ADDRESS_229530] dose of 
study  drug. Inhaled steroi ds and adrenal replacement steroid doses > [ADDRESS_229531] ive autoimmune disease.
Uncontrolled adrenal insufficiency.
Prior malignancy active within the previ ous [ADDRESS_229532].
Known history of testing positive fo r human immunodeficiency virus (HIV) or known acqui red 
immunodeficiency  syndrom e (AIDS).
Any posi tive test for hepatit is B or hepatit is C virus indicat ing acute or chronic infect ion.
Known medical condit ion (eg, a condit ion associated with diarrhea or acute diverticulit is) that, 
in the invest igator ’s opi[INVESTIGATOR_3078] n, woul d increase the risk associ ated with study participat ion or 
study  drug administrati onor interfere with the interpretation of safet y resul ts.
Major surgery  (eg, nephrectomy) less than [ADDRESS_229533] dose of study  drug.
Anti-cancer therapy  less than [ADDRESS_229534] dose of study drug.
Presence of any toxicit ies attributed to prior ant i-cancer therapy , other than alopecia, that have 
not resolved to Grade 1 (NCI CTCAE v4) or baseline before administration of study drug.
Revised Protocol No.: 02
Date: 02-Aug-2017 9
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
Any of the following laboratory  test findings:
a) WBC < 2,000/ μL
b) Neutrophils < 1,500/ μL
c) Platelets < 100,000/μL
d) AST or ALT > [ADDRESS_229535] (> [ADDRESS_229536] if liver metastases are present)
e) Total  Bilirubin > 1.[ADDRESS_229537] (except participant s with Gilbert Syndro me, who can have 
total bilirubin < 3.0 m g/dL)
f) Serum  creatinine > 1.5 x upper limit of normal  (ULN) or creatinine clearance 
< 40 mL/min (measured or calculated by [CONTACT_12021] -Gaul t formula).
Objectives and Endpoints:
Objective Endpoint
Primary
The primary object ive is to evaluate the 
difference in safet y between 
co-administered FRC nivo lumab 3 mg/kg 
and ipi[INVESTIGATOR_125] 1 mg/kg relat ive to 
sequen tially administered nivo lumab 
3mg/kg and ipi[INVESTIGATOR_125] 1mg/kg as 
measured by [CONTACT_193199] [ADDRESS_229538] scope 
SMQ with onset on the day of or within 2 days after any 
study therapy infusion d uring the combination period 
(Part 1) divided by [CONTACT_193200]. The 
analy sis of the primary endpoint will occur at the time of 
first (primary) analysis when all participants who are still 
on-treatment have had at least Part [ADDRESS_229539] ion 
narrow scope SMQ occurring within 2 days 
after any  study  therapy  infusi on during the 
combinat ion peri od (Part 1). This incidence rate 
will be defined similarly to the primary endpo int 
except that the event rate will be based on terms
within the narrow scope SMQ rather than the 
broad scope.
To evaluate drug -related Grade [ADDRESS_229540] itute Common Termino logy The second secondary endpo int is the 
drug-related Grade 3 -5 AE incidence rate 
defined using NCI CTCAE versio n 4.0 cri teria. 
The drug- related Grade 3 -5 AE rate is defined 
as number of participant s who experienced at 
Revised Protocol No.: 02
Date: 02-Aug-2017 10
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
Objective Endpoint
Criteria for Adverse Events (NCI CTCAE) 
versio n 4.[ADDRESS_229541] ive response rate 
(ORR), as determined by  [CONTACT_193201] h secondary  endpoint is ORR as 
determined by [CONTACT_122639]. The ORR is 
defined as the number o f participant s with a 
BOR of CR or PR divided by [CONTACT_193202] s. The BOR is defined as the 
best response designat ion, as determined by [CONTACT_1275], recorded between the date of 
rando mizat ion and the date of objectively  
documented progression per RECIST 1.[ADDRESS_229542]. For participant s without 
docum ented progressi on or subsequent therapy , 
all available response designations will 
contribute to the BOR assessment.
To evaluate progression free survival (PFS) The sixth secondary  endpoint is PFS. PFS i s 
defined as the time between the date of 
rando mizat ion and the first date of documented 
progression, as determined by  [CONTACT_3170], 
or death due to any  cause, whicheve r occurs 
first. Participant s who di e without a reported 
progression will be considered to have 
progressed on the date of their death. 
Revised Protocol No.: 02
Date: 02-Aug-[ADDRESS_229543] 
subsequent ant i-cancer therapy .
Overall Design:
Study Design and Duration: 
This is a Phase 2, open -label, rando mized 2-arm study  of the fixed ratio combinat ion 
(BMS -986237) ofnivolumab and ipi[INVESTIGATOR_62607] a 3:1ratio (nivo lumab 3mg/kg and ipi[INVESTIGATOR_162] b 
1mg/kg) .The study  is divided into two parts.
In Part 1, Arm A, BMS -[ADDRESS_229544].
Safety of subjects will be monitored on an ongoing basis by [CONTACT_2362]. The BMS medical 
monitor is a physician who is responsible for reviewing the safet y of patients in this study  in a 
system atic and continuous manner. This includes a review of serious and non-serious adverse 
events including all hematological and non -hematological events.
In addit ion, study  safet y is evaluated on an ongoing basis by [CONTACT_193203] y team  (MST), who operate independent ly from 
the clinical team and monitor safet y across all nivo lumab protocols, identify potential safet y 
signals, notify appropriate stakeholders of relevant findings, and implement risk management 
plans.
Numbe r of Participants: 
Enrolled : Approximately 129 participant s 
Revised Protocol No.: 02
Date: 02-Aug-2017 12
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
Randomized : 102 (to yield 100 treated, assuming 1.5% attrition)
Screen Failure Rate :It is expected that  approximately  129 participant s will  need to be enrolled 
in order to randomize 102, assuming a screen failure rate of 21%.
This number of treated participant s was chosen to achieve a sufficient level of precisi on for a 
descript ive analysis to estimate the difference in rates of AEs in the Broad Scope MedDRA
Anaphylactic React ion SMQ between the two treatm ent arms. Fifty treated participant s per arm 
will allow est imation of the rate difference within 95% confidence limits of 20% or less and will 
be supplemented by a qualitative clinical assessment of the ty pe and severit y of events to evaluate 
benefit -risk.The 20% limi t represents what is considered to be a clinically meaningful difference 
in the rates of infusio n-related reacti ons.
Treatment Arms and Duration:
Study treatment : This tri al is a two -arm, open -label, randomized study :
Part 1:
Treatment Arm A:FRC single infusio n (mix of nivolumab and ipi[INVESTIGATOR_62607] 3:1 ratio in 
that order) administered intravenously over 60 minutes
Treatment Arm B:nivolumab (3 mg/kg infused over 60 minutes) followed by [CONTACT_40105][INVESTIGATOR_43839] 
(1mg/kg infused over 30 minutes) administered intravenously with a  30-minute interval 
waiting period between the two separate infusio ns
Note: Cy cles will be defined as three weeks in the combinat ion peri od, Part 1
Part 2:
Following four doses of the combinat ion participant s will switch to nivolumab 480mgflat 
dose infused over 30 minutes q 4 weeks. There will be a 6-week interval wait time after the 
completion of the 4 combinat ion doses prior to beginning the nivo lumab mon otherapy .
Note: Cy cles will be defined as four weeks in the flat dosing period, Part 2
Discontinuation of Participant s from Treatment:
Parti cipants who advance to Part [ADDRESS_229545].  Once a patient has discont inued from treatm ent,he or shewill 
continue to be fo llowed for overall survival (OS) for approximately [ADDRESS_229546] igator’s use of a third-party  representative to assist in locating participant s that have been 
lost to fo llow up has been included in the participant ’s informed consent, then the investigator ma y 
use a Sponsor -retained third-party representative to assist site staff with obtaining participant’s 
contact [CONTACT_193204]-up portion 
of the study. The site staff and representative will consult publicly availa ble sources, such as public 
healt h registries and databases, in order to obtain updated contact [CONTACT_3031]. If after all attempts, 
Revised Protocol No.: 02
Date: 02-Aug-[ADDRESS_229547] known alive date as determined by [CONTACT_193205] ’s medical records.
Post Study Drug Access to Therapy:
At the concl usion of the study , participant s who continue to demonstrate clinical benefit will be 
eligible to receive BMS supplied study  drug. Study  drug will be provi ded via an extensi on of  the 
study , a rollo ver study  requi ring approval by  [CONTACT_186736] h authorit y and ethics co mmit tee or 
through another mechanism at the discret ion of BMS. BMS reserves the ri ght to terminate access 
to BMS supplied study drug if any  of the f ollowing occur: a) the marketing applicat ion is rejected 
by a responsible healt h authori ty; b) the study  is terminated due to safet y concerns; c) the 
participant can obtain medication from a government sponsored or private health program; or 
therapeuti c alternatives becom e available in the local market.
Study  drug includes both Investigational [Medicinal] Product (IP/IMP) andNon-invest igational 
[Medi cinal ] Product (Non-IP/Non -IMP) and can consist of the following:
The fixed ratiocombinat ion drug product is formulated by [CONTACT_193206][INVESTIGATOR_193157] a nivolumab/ipi[INVESTIGATOR_193158] -mass ratio of 3to 1. 
The composit ion and manufacturing process of these 2 drug substances are the same as those used 
for the nivo lumab and ipi[INVESTIGATOR_193159].
The Sponsor has conducted qualit y testing to demonstrate that no interacti on occurs between the 
two antibodies. The table below provides the composit ion of the three products.
Nivolumab/Ipi[INVESTIGATOR_125] 3:1 for Renal Cell Carcinoma
Component Nivolumab Ipi[INVESTIGATOR_193160] 10 mg/mL 8.57 mg/mL
Ipi[INVESTIGATOR_125] 5 mg/mL 2.85 mg/mL
Sodium Citrate 20 mM 8.57 mM
Tris Hydrochloride 20 mM 11.43 mM
Sodium Chloride 50 mM 100 mM 78.57 mM
Mannitol 3%w/v 1%w/v 1.86% w/v
Pentetic Acid 20 μM 100 μM 65.7 μM
Polysorbate 80 0.02% w/v 0.01% w/v 0.023% w/v
The study  design schemati c is presented in the figure below. The durati on of  the trial is expected 
to be [ADDRESS_229548]  
9 months of foll ow-up.
Revised Protocol No.: 02
Date: 02-Aug-2017 14
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
Revised Protocol No.: 02
Date: 02-Aug-2017 15
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
2 SCHEDULE OF ACTIVITI ES
Table 2 -1: Screening Procedural Outline ( CA209800 )
ProcedureScreening
VisitNotes
Eligibility Assessments
Informed Consent X Prior to any  screening procedures register in IRT to obtain participant
number
Inclusion/Exclusion Criteria X All inclusion/exclusion criteria should be assessed at screening and 
confirmed prior to randomization
Medical History X Including concomitant medications and prior medicatio ns for 
collection of prior cancer therapy
Tumo r Tissue Samples X Sufficient tumor tissue, a rchival or recent acquisition, (block or a 
minimum of 20 slides is requested with a minimum of 10 slides 
required ; obtained from core biopsy, punch biopsy, excisional biopsy 
or surgical specimen) confirmed to be available at Central Laboratory.
Safety Assessments
Physical Examination X
Vital Signs X BP, HR, temperature, within 14 days prior to randomization
Physical Measurements (including performance
status)X Height, weight, IMDC score, BSA and Karnofsky Performance 
Status.
Assessment of Signs and Symptoms X For screening, within [ADDRESS_229549] dose
Serious Adverse Events Assessment Continuously Serious Adverse Events from time of consent
Review of Concomitant Medications X Within 14 days prior to randomization
Revised Protocol No.: 02
Date: 02-Aug-2017 16
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
Table 2 -1: Screening Procedural Outline ( CA209800 )
ProcedureScreening
VisitNotes
Laborato ry Tests X CBC with differential, Chemistry panel including: LDH, AST, ALT, 
ALP, ALB, T.Bili, BUN or serum urea level, creatinine, corrected Ca, 
Na, K, Cl, Glucose, amylase, lipase, phosphate, TSH, Free T4, Free 
T3, within 14 days of randomization; hepatitis B surface antigen 
(HBVsAg), and hepatitis C antibody (HCV Ab) or hepatitis C RNA 
(HCV RNA), within [ADDRESS_229550] (WOCBP only) X Serum or urine (minimum sensitivity equivalent units
25IU/L or equivalent units of HCG) to be done at screening visit and 
repeated within [ADDRESS_229551] dose of study treatment .
Screening/Baseline Tumor Assessment X Chest, Abdomen, Pelvis, and Brain within [ADDRESS_229552] dose. 
Head MRI is required in participants with known history of brain 
metastases; participants without known history of brain metastases 
may have head CT or MRI
Contrast enhanced CT scan of the chest, abdomen and pelvis and all 
other known/suspected sites of disease.  Should a participant have 
contraindicatio n for CT intravenous contrast, a non -contrast CT scan 
of the chest and a contrast enhanced MRI of the abdomen and pelvis 
and all other known/suspected sites of disease.
For partici pants with known brain metastasis, an MRI brain without 
and with gadolinium is required at Screening. A brain CT is not 
allowed for participants with a history or evidence of known brain 
metastasis at Screening.
Clinical Drug Supplies
Randomize X First dose to be administered within 72 hours following 
randomization.
Revised Protocol No.: 02
Date: 02-Aug-2017 17
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
Table 2 -2: On-Study Assessments Part 1 (CA209800) 
Procedure For Part 1, Study treatment Every 3 Weeks for 
4Doses
(Both Arm A and Arm B)Notes
Cycle 1, 2, 3, 4
(Day 1)
Safety Assessments
Targeted Physical Examination X To be performed only as clinically indicated within 72 hours 
prior to dosing
Vital Signs X Including BP, HR, and temperature within 72 hours prio r to 
dosing
Physical Measurements (including
performance status)X Weight and KPS within 72 hours prior to dosing
Adverse Events Assessment Continuously For48 hours, pay close attention to any hypersensitivity, 
anaphy laxis or any  infusion related reactions.
Review of Concomitant 
MedicationsX
Laborato ry Tests X Within 72 hrs prior to dosing to include CBC w/ differential, 
LFTs, BUN or serum urea level, creatinine, corrected Ca, Na, 
K, Cl, LDH, Glucose, amylase, lipase, phosphate, TSH 
(+reflex Free T4 and Free T3)
Pregnancy Test (WOCBP only) X Serum or urine (minimum sensitivity equivalent units
25IU/L or equivalent units of HCG) within [ADDRESS_229553].
Pharmacokinetic and 
Immunogenicity Assessments
Immunogenicity blood sample X Refer to Table 9.5 -1
Revised Protocol No.: 02
Date: 02-Aug-2017 18
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
Table 2 -2: On-Study Assessments Part 1 (CA209800) 
Procedure For Part 1, Study treatment Every 3 Weeks for 
4Doses
(Both Arm A and Arm B)Notes
Cycle 1, 2, 3, 4
(Day 1)
PK Samples X Refer to Table 9.[ADDRESS_229554] tumor assessment should be performed at 12 weeks 
(±1week ) following randomization (until disease progression
ortreatment discontinuation, w hichever occurs later ).
Contrast enhanced CT Chest, CT (or MRI with and without 
contrast) abdomen, pelvis and all known sites of disease. Use 
same imaging method as was used at screening/baseline. 
Participants with a history of brain metastasis should have 
surveillance MRI (with and witho ut gadolinium approximately 
every 12 weeks, or sooner if clinically indicated (until disease 
progression ortreatment discontinuation , whichever occurs 
later)
Revised Protocol No.: 02
Date: 02-Aug-2017 19
3.0
Approved
930107718
3.0
v

Clinical Protocol CA209800
BMS -936558 nivolumab
Table 2 -2: On-Study Assessments Part 1 (CA209800) 
Procedure For Part 1, Study treatment Every 3 Weeks for 
4Doses
(Both Arm A and Arm B)Notes
Cycle 1, 2, 3, 4
(Day 1)
Outcomes Research Assessments
FACT -G,EQ-5D-3L , and FKSI -[ADDRESS_229555] questionnaire should be completed after randomization but 
before dosing. 
(Cycle 1, 3)
Health Care Utilization X Health Care Utilization will be collected at each visit
Clinical Drug Supplies
IRT Drug Vial Assignment X Within [ADDRESS_229556] dose to be administered within 72 hours following 
randomization .
Revised Protocol No.: 02
Date: 02-Aug-2017 20
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
Table 2 -3: On-Study Assessments -Part 2 (CA209800)
Procedure For Part 2, Study treatment is 
Administered Every 4 Weeks
(Both Arm A and Arm B)Notes
Cycle 5 will begin 6 weeks after Cycle 4
Cycle 5 and beyond
(Day 1)
Safety Assessments
Targeted Physical Examination X To be performed only if clinically indicated within 72 hours prior to dosing
Vital Signs X Including BP, HR, and temperature within 72 hours prio r to dosing
Physical Measurements (including 
performance status)X Weight and KPS within 72 hours prior to dosing
Adverse Events Assessment Continuously
Review of Concomitant 
MedicationsX
Laborato ry Tests X Beginni ng at Cycle 5 and every alternate dose thereafter (Cycle 7, 9, 11, 13, etc .), 
on-study local laboratory assessments should be done within 72 hours prior to 
dosing and include: CBC w/differential, LFTs (ALT, AST, total bilirubin, alkaline 
phosphatase), BUN or serum urea level, creatinine, corrected Ca, Na, K, Cl, LDH, 
glucose, amy lase, lipase, phosphate, TSH with reflexive Free T4, Free T3.
Beginning at Cycle 6 and every alternate dose thereafter (Cycle 8, 10, 12, 14, 
etc.), on-study local laboratory assessment should be done within 72 hours prior to 
dosing and include: LFTs (ALT, AST, total bilirubin, alkaline phosphatase) and 
creat inine.
Pregnancy Test (WOCBP only) X Serum or urine (minimum sensitivity equivalent units
25IU/L or equivalent units of HCG) every [ADDRESS_229557] -G, EQ-5D-3L , and FKSI -19 X To be completed at the start of the clinic visit every 4 weeks from Cycle 5 
onwards
Health Care Utilization X Health Care Utilization will be collected at each visit from Cycle 5 onwards
Revised Protocol No.: 02
Date: 02-Aug-2017 21
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
Table 2 -3: On-Study Assessments -Part 2 (CA209800)
Procedure For Part 2, Study treatment is 
Administered Every 4 Weeks
(Both Arm A and Arm B)Notes
Cycle 5 will begin 6 weeks after Cycle 4
Cycle 5 and beyond
(Day 1)
Pharmacokinetic and 
Immunogenicity Assessments
Immunogenicity blood sample X Refer to Table 9.[ADDRESS_229558] tumo r assessment during Part 2 should occur after 8 weeks (± 1 week ) 
relative to previous tumor assessment performed at Week 12.
Subsequent tumor assessments should occur every 8 weeks (± 1 week ) for the first 
12 months from randomization.
From the second year from randomization, tumor assessments should occur ever y 
12 weeks (± 2 weeks ) until disease progression ortreatment discontinuation , 
whichever occurs later .
Contrast enhanced CT Chest, CT (or MRI with and without contrast)) abdomen, 
pelvis and all known sites of disease. Use same imaging method as was used at 
screening/baseline.
Participants with a history of brain metastasis should have surveillance MRI brain 
with and without gadolinium approximately every 12 weeks, or sooner if 
clinically indicated (until disease progression ortreatment discontinuation , 
whichever occurs later ).
Clinical Drug Supplies
IRTDrug Vial Assignment X
Administer Study Treatment X Note: Within [ADDRESS_229559] receive the dose 
of study medication.
Revised Protocol No.: 02
Date: 02-Aug-2017 22
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
Table 2 -4: Follow -up Assessments (CA209 800)
ProcedureFollow Up ,a
Visits X1 and 
X2Survival ,b
Follow -up Y 
VisitsNotes
Safety Assessments
Targeted Physical Examination X To assess for potential late emergent study treatment related issues
Adverse Event Assessments X X
Laborato ry Tests X On site/local CBC w/differential, LFTs, BUN, creatinine, amylase, lipase 
and TSH (+ reflex Free T4 and Free T3) for X1, repeat at X2 if study 
treatment related toxicity persists.
Pregnancy Test (WOCBP Only) X Serum or urine
Review of Concomitant Medications X
Pharmacokinetic Samples  and 
Immunogenicity Assessments
PK Samples X Refer to Table 9.[ADDRESS_229560], to include subsequent anti -cancer therapy
Efficacy Assessments
Tumo r Assessments See Notes Only for participants without progression on study therapy.
SUBSEQUENT tumor assessments should continue to occur ever y 8 weeks 
(±1 week ) thereafter for the first 12 months, then ever y 12 weeks
(± 2 weeks )until disease progression or treatment discontinuation, 
whichever occurs later .
Contrast enhanced CT Chest, CT (or MRI with and without contrast) 
abdomen, pelvis and all known sites of disease. Use same imaging method 
as was used at screening/baseline.
Participants with a history of brain metastasis should have surveillance MRI
Revised Protocol No.: 02
Date: 02-Aug-2017 23
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
Table 2 -4: Follow -up Assessments (CA209 800)
ProcedureFollow Up ,a
Visits X1 and 
X2Survival ,b
Follow -up Y 
VisitsNotes
Brain without and with gadolinium approximately every 12 weeks, or sooner 
if clinically indicated (until disease progression or treatment discontinuation, 
whichever occurs later ).
Outcomes Research Assessments
FACT -G and FKSI -[ADDRESS_229561] year and 6 months thereafter
Health Care Utilization X Collection done at X1 and X2 only
aX visits occur as follows -X1 = [ADDRESS_229562] dose ( 7 days) or coincide with the date of discontinuation ( 7 days) if date of discontinuation is greater 
than [ADDRESS_229563] dose, X2 = 84 days (7 days) from follow -up visit 1. Follow up visits X1 and X2 will occur only after participant completes all study 
treatment. Participant s must be followed for at least [ADDRESS_229564] dose of study treatment. 
bY [CONTACT_193207] = every 3 months from X2 (7 days). Survival Follow -up visits to occur every [ADDRESS_229565] s.
For responders (CR, PR or SD) on study beyond 2 years an extension of the frequency of scans from every 12 weeks to ever y 24 weeks until disease progression 
ortreatment discontinuation, whichever occurs later, is permitted. Participant s who discontinue study therapy for reasons other than progression should continue 
to be scanned until disease progression is d ocumented. 
If a dose is delayed, the procedures scheduled for that same timepoint should also be delayed to coincide with when that timep oint’s dosing actually occurs.
Revised Protocol No.: 02
Date: 02-Aug-2017 24
3.0
Approved
930107718
3.0
v

Clinical Protocol CA209800
BMS -936558 nivolumab
 
 
 
4 OBJECTIVES AND ENDPO INTS
Table 4 -1: Objectives and Endpoints
Objective Endpoint
Primary
To evaluate the difference in safety between co -
administered FRC nivolumab 3 mg/kg and 
ipi[INVESTIGATOR_125] 1 mg/kg relative to sequentially 
administered nivolumab 3 mg/kg and ipi[INVESTIGATOR_125] 
1mg/kg as measured by [CONTACT_193208] [ADDRESS_229566] scope 
SMQ with onset on the day of or within 2 days after any 
study therapy infusion during the combination period 
(Part 1) divided by [CONTACT_193200] . The 
analy sis of the primary endpoint will occur at the time of 
first (primary) analysis when all participants who are still 
on-treatment have had at least Part [ADDRESS_229567] secondary endpoint is the incidence of AEs in 
the MedDRA Anaphylactic Reaction narrow scope SMQ 
occurring within 2 days after any study therapy infusion 
during the combination period (Part 1). This incidence 
rate will b e defined similarly to the primary endpoint 
except that the event rate will be based on terms within 
the narrow scope SMQ rather than the broad scope.
To evaluate drug- related Grade 3 -5 AE incidence 
rate  defined using National Cancer Institute 
Common Terminology Criteria for Adverse Events 
(NCI CTCAE) version 4.[ADDRESS_229568] 
dose of study treatment, divided by [CONTACT_193209] s.
Revised Protocol No.: 02
Date: 02-Aug-2017 34
3.0
Approved
930107718
3.0
v

Clinical Protocol CA209800
BMS -936558 nivolumab
Table 4 -1: Objectives and Endpoints
Objective Endpoint
To determine PK comparisons of nivolumab and 
ipi[INVESTIGATOR_193161] .The fo urth secondary endpoint is PK comparisons of 
nivolumab and ipi[INVESTIGATOR_193162]. PK 
will be measured using serum concentration -time data.
To evaluate the objective response rate (ORR), as 
determined by [CONTACT_193210]. The ORR is defined as the number of 
participant s with a BOR of CR or PR divided by [CONTACT_193211] s. The BOR is defined as the 
best response designation, as determined by [CONTACT_1275], recorded between the date of randomization 
and the date of objectively documented progression per 
RECIST 1.[ADDRESS_229569]. For 
participant s without documented progression or 
subsequent therapy, all available response designations 
will co ntribute to the BOR assessment.
To evaluate progression free survival (PFS) The sixth secondary endpoint is PFS. PFS is defined as 
the time between the date of randomization and the first 
date of documented progression, as determined by [CONTACT_1275], or death due to any cause, whichever occurs 
first. Participant s who die without a reported progression 
will be co nsidered to have progressed on the date of their 
death. Participant s who did not progress or die will be 
censored on the date of their last evaluable tumor 
assessment. Participant s who did not have any on study 
tumor assessments and did not die will be cen sored on 
their date of randomization. Participant s who started 
anti-cancer therapy without a prior reported progression 
will be censored on the date of their last evaluable tumor 
assessment prior to the initiation of first subsequent 
anti-cancer thera py in cluding radiotherapy, tumor 
directed surgery, or systemic anticancer therapy.
 
 
 
 
  
 
 
 
 
 
 
 
Revised Protocol No.: 02
Date: 02-Aug-2017 35
3.0
Approved
930107718
3.0
v

Clinical Protocol CA209800
BMS -936558 nivolumab
 
 
 
 
 
 
 
 
 
  
 
 
 
 
  
 
 
 
  
 
 
 
 
5 STUDY DESIGN
5.1 Overall Design
This is a Phase 2, open -label, rando mized 2-arm study  of the fixed ratio combinat ion 
(BMS -986237) of nivolumab and ipi[INVESTIGATOR_62607] a 3:1 ratio (nivo lumab 3mg/kg and ipi[INVESTIGATOR_162] b 
1mg/kg) in participant s with previ ously untreated advanced or m etastatic RCC.
Parti cipants meet ing all eligibilit y criteria will be rando mized 1:1 ratio and stratified by [CONTACT_193212] c score (0 vs 1 -2 vs 3 -6)to Arm A ( BMS -986237) or Arm B ( nivolumab and ipi[INVESTIGATOR_193163]).
In Part 1, Arm A, BMS -986237 will be a dministered as one 60 -minute infusio n, every 3 weeks for 
up to 4 doses.
Revised Protocol No.: 02
Date: 02-Aug-[ADDRESS_229570] .
The study  design schemat ic is presented in Figure 5.1 -1.
Figure 5.1 -1: Study Design Schematic
Physical examinat ions, vital sign measurements and clinical  laboratory  evaluat ions will be 
performed at selected times throughout the dosing interval. Parti cipants will be closely mo nitored 
for adverse events throughout the study .
5.1.1 Data Monitoring Committee and Other External Committees
Not applicable.
5.2 Number of Participants
It is expected that  approximately 129 participant s wil l need to be enrolled in order to randomize 
102, assuming a screen failure rate of 21%.
This number of [ADDRESS_229571] Scope MedDRA 
Revised Protocol No.: 02
Date: 02-Aug-[ADDRESS_229572] imation of the rate difference within 95% confidence limits of 20% or less and will 
be supplemented by a qualitative clinical assessment of the type and severit y of events to evaluate 
benefit -risk.The 20% limi t represents what is considered to be a clinically meaningful difference 
in the rates of infusio n-related reacti ons.
5.[ADDRESS_229573] of 3 phases: screening, treatment, and follow -up.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revised Protocol No.: 02
Date: 02-Aug-2017 38
3.0
Approved
930107718
3.0
v

Clinical Protocol CA209800
BMS -936558 nivolumab
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revised Protocol No.: 02
Date: 02-Aug-2017 39
3.0
Approved
930107718
3.0
v

Clinical Protocol CA209800
BMS -936558 nivolumab
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revised Protocol No.: 02
Date: 02-Aug-[ADDRESS_229574] be met.
6.1 Inclusion Criteria
1)Signed Writ ten Informed Consent
a)Parti cipants must have signed and dated an IRB/IEC approved written informed consent  
form in accordance with regulatory  and institutional guidelines. This must be obtained 
before the performance of any protocol  related procedures that are not part of normal 
participant care
b)Parti cipants must be willing and able to comply with scheduled visits, treatment schedule, 
laboratory  tests including the completion of quality of life questi onnai res and other 
requi rements of the study
2)Type of Participant and Target Disease Characteristics
a)Histological confi rmation of RCC with a clear -cell com ponent
Revised Protocol No.: 02
Date: 02-Aug-2017 41
3.0
Approved
930107718
3.0
v

Clinical Protocol CA209800
BMS -936558 nivolumab
b)Advanced (not amenable to curative surgery  or radiat ion therapy ) or metastatic (AJCC 
Stage IV) RCC
c)No pri or sy stemic therapy  for RCC wi th the following except ion:
i. One prior adj uvant or neoadjuvant therapy  for completely  resectable RCC if such 
therapy  did not include a checkpo int inhibitor and if recurrence occurred at least 
6months after the last dose of adjuvant or neoadjuvant therapy.
d)Karno fsky Performance Status (KPS) of at least 70%
e)Measurable disease as per RECIST 1.1
f)Tumor tissue (form alin-fixed paraffin -embedded (FFPE) archival or recent acquisit ion) 
must be received   by  [CONTACT_193198] (bl ock or unstained slides) in order to random ize 
a participant to study  treatm ent.  (Note: Fine Needle Aspi[INVESTIGATOR_57774] [FNA] and bone 
metastases samples are not acceptable for submission).
i. If an insufficient amount of tumor tissue fro m an unresectable or metastatic site is 
available prior to the start of the screening phase, subjects must consent to allow 
the acqui sition of addi tional tumor tissue for performance o f biomarker analyses
g)Parti cipants with favorable, intermediate and poor risk categories will be eligible for the 
study . 
i. To be eligible for the Interm ediate -Risk cohort one or two of the following 
prognosti c factors as perInternational Metastatic RCC Database Consorti um 
(IMDC) risk factors include :
i.KPS equal to 70%
ii.Less than [ADDRESS_229575]
iv.Corrected calcium concentration greater than 10 mg/dL
v.Absolute neutrophil count greater than the ULN
vi.Platelet coun t greater than the ULN
ii. If more than two factors are present they will be eligible forPoor -Risk cohort. If 
none of the above factors are present, participant s are only eligible for the 
Favorable -Risk cohort. 
3)Age and Reproductive Status
a)Males and Females, 18 years of age 
b)Women of childbearing potential  (WOCBP) must have a negat ive serum or urine 
pregnancy test (minimum sensit ivity 25 IU/L or equivalent units of HCG) within [ADDRESS_229576] not be breastfeeding
c)Women of childbearing potenti al (WOCBP) must agree to follow instructi ons for 
method(s) of contraception, as indicated in the informed consent form, for a period of 
30days (durati on of  ovulatory cycle) pl us the time requi red for the investi gational drug to 
undergo approximately five half-lives. WOCBP shoul d theref ore use an adequate m ethod 
Revised Protocol No.: 02
Date: 02-Aug-2017 42
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
to avoid pregnancy for 5 months (30 days plus the time required for nivo lumab to undergo 
approximately  five half lives) after the last dose of invest igational drug (combinat ion or 
monotherapy ). 
d)Males who are sexually active with WOCBP must agree to followinstructi ons for 
method(s) of contraception, as indicated in the informed consent form, for a period of 
90days plus the time requi red for the invest igational drug to undergo approximately five 
half-lives. Men who are sexually active with WOCBP must conti nue contracepti on for 
7months (90days plus the time requi red for nivolumab to undergo approximately five 
half-lives) after the last dose of invest igational drug (com binat ion or monotherapy ). In 
addition, male participant s must be willing to refrain fro m sperm  donat ion during this time.
e)Azoospermic males are exempt from contraceptive requi rements. WOCBP who are 
continuously not heterosexually active are also exem pt from contraceptive requi rements, 
and st ill must undergo pregnancy testing as described in th is section.
Invest igators shall counsel WOCBP, and male participant s who are sexually act ive with WOCBP, 
on the importance of pregnancy preventi on and the implicat ions of an unexpected pregnancy. 
Invest igators shall advise on the use of highly effective methods of contraception, (Appendix [ADDRESS_229577] a failure rate of < 1% when used consistently and correctly.
6.2 Exclusion Criteria
1)Medical Conditions
a)Active brain metastases or leptom eningeal  metastases. Parti cipant s with brain metastases 
are eligible if these have been treated and there is no m agnetic resonance imaging (MRI -
except where contraindicated in which CT scan is acceptable) evidence of progression for 
at least [ADDRESS_229578] dose of study 
treatm entadministration .
b)Ocul ar melanom a
c)Prior malignancy act ive within the previous [ADDRESS_229579].
d)Known history  of posi tive test for human immunodeficiency virus (HIV) or known 
acqui red immunodeficiency syndrome (AIDS). NOTE: Testing for HIV must be 
perform ed at si tes where m anda ted locally
e)Any posi tive test result for hepatit is B virus or hepatit is C virus indicat ing presence of 
virus, egHepati tis B surface ant igen (HBsAg, Australia ant igen) posit ive, or Hepatit is C 
antibody  (anti-HCV) posi tive (except if HCV -RNA negat ive)
f)Known medical condi tion (eg, a condi tion associ ated wi th diarrhea or acute divert iculitis) 
that, in the investigator’s opi[INVESTIGATOR_3078] n, woul d increase the risk associ ated with study 
participat ion or study treatment administration or interfere with the interpretation of safet y 
resul ts.
g)Major surgery  (eg, nephrectomy) less than [ADDRESS_229580] dose of study  treatment .
Revised Protocol No.: 02
Date: 02-Aug-2017 43
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
h)Anti-cancer therapy less than [ADDRESS_229581] dose of study  treatm ent.
i)Presence of any toxicities attributed to prior anti -cancer therapy , other than alopecia, that 
have not resolved to Grade 1 (NCI CTCAE v4) or baseline before administration of study 
treatm ent.
2)Prior/Concomitant Therapy
a)Prior treatm ent wi th an ant i-PD-1, anti -PD-L1, anti -PD-L2, anti-CD137 , or anti -CTLA -4 
antibody , or any  other antibody  or drug specifically  targeting T -cell co -stimulat ion or 
checkpoint pathways
b)Any act ive or recent history of a known or suspected autoimmune disease or recent history 
of a syndro me that required systemic corticosteroids (> 10 mg daily prednisone equivalent) 
or immunosuppressive medications except for syndromes which would not be expected to 
recur in the absence of an external  trigger. Particip ants with vitiligo or typeI diabetes 
mellitus or residual hypothyroidism due to autoimmune thyro iditis only requiring hormone 
replacement are permitted to enroll.
c)Any condit ion requiring systemic treatment with corticosteroids (> 10 mg daily prednisone 
equivalents) or other immunosuppressive medications within [ADDRESS_229582] dose of 
study  treatm ent. Inhaled steroi ds and adrenal  replacement steroi d doses > 10 mg daily 
prednisone equivalents are permitted in the absence of active autoimmune disease.
d)Uncontrolled adrenal insufficiency.
3) Physical and Laboratory Test Findings
a)Any of the fo llowing laboratory  test findings:
i. WBC < 2000/μL
ii. Neutrophils < 1500/μL
iii. Platelets < 100*103/μL
iv. Hem oglobin < 9.0 g/dL
v. Serum  creatinine  >1.[ADDRESS_229583] or ca lculated creatinine clearance 
< 40 mL/min (using the Cockcroft -Gaul t formula)
vi. AST/ALT: > 3.[ADDRESS_229584]
vii. Total  bilirubin > 1.[ADDRESS_229585] ( participants with Gilbert Syndro me who m ust 
have a total  bilirubin level  of <3.0x ULN)
viii. Any posi tive test result for hepatit is B virus or hepatit is C virus indicat ing 
presence of virus, egHepati tis B surface ant igen (HBsAg, Australia ant igen) 
positive, or Hepatitis C ant ibody  (anti -HCV) posi tive (except if HCV -RNA 
negat ive).
4)Allergies and Adverse Drug Reaction
a)History  of allergy  or hy persensi tivity to study  treatment components
5)Other Exclusion Criteria
a)Prisoners or participant s who are involuntarily incarcerated. (Note: under certain specific 
circumstances a person who has been imprisoned may be included or permitted to continue 
as a participant . Stri ct condi tions apply and Bristol -Myers Squibb approval is required ).
Revised Protocol No.: 02
Date: 02-Aug-2017 44
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
b)Parti cipants who are compulsorily detained for treatment of either a psychiatric or physica l 
(eg, infect ious disease) illness
Eligibilit y criteria for this study  have been carefully considered to en sure the safety  of the study 
participant s and that the resul ts of the study  can be used. It is imperative that participant s fully 
meet all eligibilit y criteria.
6.[ADDRESS_229586] ions are required .
6.4 Screen Failures
Screen failures are defined as parti cipants who consent to parti cipate in the clinical study  but are 
not subsequently randomized. A minimal set of screen failure information is requi red to ensur e 
transparent reporting of screen failure participants, to meet the Consolidated Standards of 
Reporting Trials (CONSORT) publishing requirements, and to respond to queries fro m regulatory 
authori ties. Minimal information includes date of consent, demograph y, screen failure details, 
eligibilit y criteria, and any serious AEs.
6.4.1 Retesting During Screening or Lead -In Period
Parti cipant Re-enrollment: This study  permit s the re-enrollment of a participant that has 
discontinued the study as a pre -treatm ent failure ( ie, participant has not been rando mized / has not 
been treated). If re- enrolled, the participant must be re -consented .
Retesting of laboratory  parameters and/or other assessments within any single Screening or 
Lead -in period will be permitted (in addit ion to any parameters that require a confirmatory value).
The most current resul t prior to Rando mizat ion is the value by [CONTACT_53962] n will be 
assessed, as it represents the participant ’s most current, clinical state.
Laboratory  parameters and/or asses sments that are included inTable 2-1, Screening Procedural 
Outline may be repeated in an effort to find all possible well-qualified participant s. Consultatio n 
with the Medi cal Monitor may be needed to ident ify wheth er repeat testing of any particular 
param eter is clinically relevant.
[ADDRESS_229587] igational treatment(s), marketed product(s), placebo or 
medical device intended to be administered to a study participant according to the study 
rando mizat ion or treatment allocat ion.
Study  treatment includes both Invest igational [Medicinal] Product (IP/IMP) and 
Non-invest igational [Medicinal] Product (Non -IP/Non -IMP).
In thi s protocol , invest igational products are:
Nivo lumab
Ipi[INVESTIGATOR_102259].: 02
Date: 02-Aug-2017 45
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
Nivolumab/Ipi[INVESTIGATOR_193164] (FRC) .
The fixed ratio combinat ion drug product is formulated by [CONTACT_193206][INVESTIGATOR_193157] a nivolumab/ipi[INVESTIGATOR_193158] -mass ratio of 3 to 1. 
The Sponsor has conducted qualit y testing to demonstrate that no interacti on occurs between the 
two antibodies. The table below provides the composit ion of the three products .
Table 7 -1: Nivolumab/Ipi[INVESTIGATOR_125] 3:1 for Renal Cell Carcinoma
Component Nivolumab Ipi[INVESTIGATOR_193160] 10 mg/mL 8.57 mg/mL
Ipi[INVESTIGATOR_125] 5 mg/mL 2.85 mg/mL
Sodium Citrate 20 mM 8.57 mM
Tris Hydrochloride 20 mM 11.43 mM
Sodium Chloride 50 mM 100 mM 78.57 mM
Mannitol 3% w/v 1% w/v 1.86% w/v
Pentetic Acid 20 μM 100 μM 65.7 μM
Polysorbate 80 0.02% w/v 0.01% w/v 0.023% w/v
An invest igational product, also known as invest igational medicinal product in some regions, is 
defined a pharmaceut ical form of an active substance or placebo being tested or used as a reference 
in a clinic al study , including products already with a market ing authorization but used or 
assembled (formulated or packaged) different ly than the authori zed form, or used for an 
unauthori zed indication, or when used to gain further information about the authorized f orm.
Other medications used as support or escape medication for preventative, diagnosti c, or therapeutic 
reasons, as components of the standard of care for a given diagnosis, may be considered as 
non-invest igational products.
Revised Protocol No.: 02
Date: 02-Aug-2017 46
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
Table 7 -2: Study treatment s for CA209800
Product Description / 
Class and Dosage 
FormPotency Primary Packaging 
(Volume)/Label Typ eSecondary Packaging 
(Qty)/Label TypePackaging / 
AppearanceStorage Conditions
(per label)
Nivolumab Solution for 
Injection100 mg (10 mg/mL)
or
40 mg (10 mg/mL)10 mL per vial 
Or
4 mL vial/Open label5 or 10 vials per carton/ 
Open -label
Or 
240 mg kits (2 - 100 mg 
vials & 1 - 40 mg vial)Clear to opalescent 
colorless to pale yellow 
liquid. May contain 
particles2°Cto 8°C. Protect 
from light and freezing
Ipi[INVESTIGATOR_125] 200 mg (5 mg/mL) 40 mL per vial/Open -
label4 vials per 
carton/Open -labelClear to opalescent 
colorless to pale yellow 
liquid. May contain 
particles2°Cto 8°C. Protect 
from light and freezing
BMS -986237 Solution 
for Injection
(Nivolumab/Ipi[INVESTIGATOR_193165])240mg Nivolumab/ 
80 mg Ipi[INVESTIGATOR_125]28mL per vial/Open -
label
(vial with booklet 
label -first page in 
ORANGE)6 vials per 
carton/Open -labelClear to opalescent, 
colorless to pale yellow 
liquid. Light (few) 
particulates may be 
present2°Cto 8°C. Protect 
from light and freezing
Revised Protocol No.: 02
Date: 02-Aug-2017 47
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
7.1 Treatments Administered
7.1.1 Part 1 Study Treatment Administration
In Part 1 of the study  there will be two treatment arms:
Arm ABMS -986237 (nivo lumab 3mg/kg/ipi[INVESTIGATOR_125] 1mg/kg as a single infusio n) will be 
administered as one 60-minute infusio n on Day [ADDRESS_229588]. Participant s shoul d receive 
nivolumab at a dose of 3 mg/kg as a [ADDRESS_229589].Participants should begin study  treatment within 3calendar days of 
randomizat ion.
The second infusio n will always be ipi[INVESTIGATOR_125], and t he time in between infusions is expected to 
be approximately  30 minutes but may be more or less depending on the situation.Parti cipants 
shoul d receive ipi[INVESTIGATOR_170] a dose of 1 m g/kg as a 30-minute IV infusio n, on Day [ADDRESS_229590]. 
Dosing calculat ions should be based on the body weight assessed a t baseline. It is not necessary to 
re-calculate subsequent doses if the participant weight is within 10% of the weight used to calculate 
the previous dose. All doses shoul d be rounded up or to the nearest milligram per institutional 
standard.
The nivo lumab infusio n must be prompt ly followed by a saline flush to clear the line o f nivo lumab 
before starting the next infusio n.
Both agents given as single agent s are uncommo nly associ ated wi th infusio n reacti ons, incidence 
less than 1% for ipi[INVESTIGATOR_125] (YervoyFDA Label ) and for nivolumab 3%(OpdivoFDA Label) . 
In the CA209069 study , hypersensit ivity/infusion reacti ons were listed as 3.2% for the 
combinat ion and 2.2% for ipi[INVESTIGATOR_125]. No Grade 3 or Grade 4 hypersensit ivity/infusio n reactions 
were observed in eit her the combinat ion or single agent ipi[INVESTIGATOR_193166].[ADDRESS_229591] be resumed on the same day.
Revised Protocol No.: 02
Date: 02-Aug-[ADDRESS_229592] co-administered dose in Part 1, participant s will be administered a 
flat dose 480 mg nivo lumab 30-minute infusio n every  4 weeks (Q4W) unt il unacceptable toxicit y 
or disease progressi onis reached, whichever comes first .
Participants may be dosed up to 3 days after the scheduled date if necessary . Sub sequent dosing 
shoul d be based on the actual  date of administration of the previous dose of drug. Every  effort 
shoul d be made to adhere to protocol treatm ent schedule of administration of nivolumab every 
4weeks in the maintenance phase. In extenuat ing circumstances in which the participant cannot 
make the dosing schedule within the 3 -day window, BMS Medi cal Moni tor shoul d be contact[INVESTIGATOR_530]. 
Note: Subjects who advance to Part [ADDRESS_229593] .
For details on prepared drug storage, preparation, and administration, please refer to the 
nivolumab, ipi[INVESTIGATOR_193167] -986237 IBs and/or pharmacy reference sheets. The select ion 
and timing of dose for each participant is as fo llows:
7.1.3 Selection and Timing of Dose
Table 7.1.3 -1: Selection and Timing of Dose Part 1 (Arm A)(Administered as one 
60-minute infusion, every 3 weeks for up to 4 doses ).
Study Treatment Unit dose 
strength(s)/Dosage 
level(s)Dosage formulation
Frequency of 
AdministrationRoute of Administration
BMS -986237 4mg/kg Every 3 Weeks
(4 total doses)IV
Revised Protocol No.: 02
Date: 02-Aug-2017 49
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
Table 7.1.3 -2: Selection and Timing of Dose Part 1 (Arm B) - (Administered 
sequentially within the same day, as two separate infusions, one 
60-minute nivolumab infusion and one 30 -minute ipi[INVESTIGATOR_193168] a 30 minute break between each infusion, every 
3weeks for up to 4 doses )
Study Treatment Unit dose 
strength(s)/Dosage 
level(s)Dosage formula tion
Frequency of 
AdministrationRoute of Administration
nivolumab 3mg/kg Every 3 Weeks
(4 total doses)IV
ipi[INVESTIGATOR_125] 1mg/kg Every 3 Weeks
(4 total doses)IV
Table 7.1.3 -3: Selection and Timing of Dose Part 2 (All Participant s)-
(Administered as infusion over 30 minutes every four weeks in Part 
2 until progression or unacceptable toxicity )
Study Treatment Unit dose 
strength(s)/Dosage 
level(s)Dosage formulation
Frequency of 
AdministrationRoute of Administration
nivolumab 480mg Every [ADDRESS_229594] be prom ptly followed by a saline flush to clear the 
line of nivo lumab before starting the ipi[INVESTIGATOR_186700] n. The second i nfusio n will always be the 
ipi[INVESTIGATOR_193169], filters changed 
and participant has been observed to ensure no infusion reaction has occurred. The time in between 
infusio ns is expected to be approximately 30 minutes but may be more or less depending on the 
situation.
There will be no dose escalat ions or reductions of study  treatment allowed. For Q4W dosing 
cycles, participant s may be dosed within a 3-day window. Premedicat ions are not recommen ded 
for the first dose of nivo lumab.
Parti cipants shoul d be carefully monitored for infusio n react ions during study  treatm ent
administration. If an acute infusion react ion is noted, participant s should be managed according to 
Secti on 7.4.[ADDRESS_229595] ion is to be administered as a ~ 60- minute IV infusio n through a 0.2-micron to 
1.2-micron pore size, low-protein binding (polyethersulfo ne membrane) in-line filter at the 
Revised Protocol No.: 02
Date: 02-Aug-[ADDRESS_229596] ion. Nivo lumab injection can be infused undiluted (10 mg/mL) or diluted with 0.9% Sodiu m 
Chloride Inject ion, USP or 5% Dextrose Injection, USP to protei n concentrati ons as low as 
0.35 mg/mL. During drug product preparation and handling, vigorous mixing or shaking is to be 
avoided. Instructions for diluti on and infusio n of nivolumab injection are provi ded in the clinical 
protocol , pharmacy binder, pharmacy manual, or pharmacy reference sheet. Care must be taken to 
assure sterili ty of the prepared solution as the product does not contain any antimicrobial 
preservat ive or bacteriostatic agent. Nivo lumab infusio ns are compatible with polyvinyl chloride 
(PVC) or polyo lefin containers and infusio n sets, and glass bottles. Vials of nivolumab inject ion 
must be stored at 2 C to 8C (36 F to 46F) and protected from light and freezing.
Ipi[INVESTIGATOR_193170] a 
PVC, non-PVC/non -DEHP or glass container and is stable for 24 hours at 2° -8°C or room 
temperature/room  light (RT/RL). For ipi[INVESTIGATOR_193171], refer to ipi[INVESTIGATOR_193172]/or pharmacy reference sheets.
Separate i nfusi on bags and filters shoul d be used when administering nivolumab and ipi[INVESTIGATOR_162] b 
on the same day .
Ipi[INVESTIGATOR_186704] a ~30 minute IV infusio n, using a volumetric pump with a 
0.2to 1.2 micron in-line filter at the protocol -specified dose. The drug can be diluted with 0.9% 
norm al saline or 5% Dextrose Injection toconcentrati ons between 1 mg/mL and 4 mg/mL. It is 
not to be administered as an IV push or bol us injections. Care must be taken to assure sterili ty of 
the prepared sol utions, since the drug product does not con tain any ant imicrobial preservat ives or 
bacter iostatic agents. At the end of the infusio n, flush the line with a sufficient quantit y of normal 
saline or 5% dextrose solution.
BMS -[ADDRESS_229597] ion is 
diluted with 0.9% Sodium Chloride Inject ion, [LOCATION_002] Pharmacopeia (USP) to required 
concentrati ons.
BMS -986237 is available as a solution at a concentration of 11.4 mg/mL. The volume for 
calculated weight based dose (refer to pharmacy reference sheets) is to be added to 40 mL of 0.9% 
Sodium Chloride (normal saline) USP prior to being administered to the participant as an infusion, 
at a flow rate of less than or equal to 2.5 mL /min over ~ [ADDRESS_229598] be stored at 2to 8C (36to 46F) protected from light and it 
must not be frozen. Further instructions for dilution and infusio n of BMS -[ADDRESS_229599] does not contain any  antimicrobial 
preservat ive or bacteriostatic agent. No incompatibilit ies between BMS -986237 and polyvinyl 
chloride (PVC) an d poly olefin containers/IV components have been observed. 
Revised Protocol No.: 02
Date: 02-Aug-2017 51
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
7.2 Method of Treatment Assignment
All part icipants will be centrally  randomized or using an Interactive Response Techno logy(IRT). 
Before the study  is initiated, each user will receive log in informat ion and directions on how to 
access the IR T.
Once enro lled in IRT, enrolled subjects that have met all eligibilit y criteria will  be ready  to be 
rando mized through the IRT. The fo llowing informat ion is required for subject randomizat ion:
Subject number
Date of birth
IMDC prognostic score at screening (0 vs 1- 2 vs 3 -6)
Subjects meet ing all eligibili ty criteria will be rando mize d in a1:[ADDRESS_229600] ivities (Section 2). 
7.3 Blinding
This is an open -label study; however, the specific treatm ent to be taken by a participant will be 
assigned using an Interactive Response Techno logy(IRT). The site will contact [CONTACT_193213]. The site 
will record the treatment assignment on the applicable case report form, if required.
7.[ADDRESS_229601] be delayed until treatment can resum e. Tum or assessments for all 
participant s should cont inue as per prot ocol even if dosing is delayed.
Nivo lumab, i pi[INVESTIGATOR_125], and BMS -986237 administration should be delayed for the fo llowing:
Grade 2 non -skin, drug- related adverse event, with the exception o f fatigue
Grade [ADDRESS_229602], ALT and/or Total Bilirubin abnormalit ies
Grade 3 skin, drug -related adverse event
Grade 3 drug -related laboratory abnormalit y, with the following except ions: 
oGrade 3 lymphopenia or asymptomat ic amylase or lipase does not require dose 
delay
oGrade [ADDRESS_229603], ALT, Total Bilirubin will require dose discont inuat ion (see Section
7.4.3 )
Any adverse event, laboratory  abnorm ality, or intercurrent illnes s which, in the j udgment of 
the invest igator, warrants delaying the dose of study medicat ion.
Revised Protocol No.: 02
Date: 02-Aug-2017 52
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
Parti cipants who requi re delay of study  treatment shoul d be re-evaluated weekly  or more 
frequently if clinically indicated and resume study  treatm entdosing when re -treatm ent cri teria are 
met.
7.4.2 Criteria to Resume Treatment
Parti cipants may resume treatm ent with study  treatment when the drug-related AE(s) resolve to 
Grade 1 or baseline value, with the fo llowing excepti ons:
Parti cipants may  resume treatm ent in the presence of Grade 2 fat igue
Parti cipants who have not experienced a Grade 3 drug-related skin AE may resume treatment 
in the presence of Grade 2 skin toxicit y
For parti cipants wi th Grade [ADDRESS_229604], ALT and/or Total Bilirubin abnormalit ies, dosing may 
resum e when laboratory  values return to baseline and management with corticosteroids , if 
needed, is complete.
Parti cipants wi th combined Grade [ADDRESS_229605]/ALT AND total bilirubin values meet ing 
discontinuat ion parameters (Section 7.4.3 )should have treatment permanent ly discont inued. 
Drug-related pulmo nary toxicity,diarrhea or colit isor myocardi tismyositis, rhabdo myolysis
must have reso lved to baseline before treatment is resumed. Participants with persistent 
Grade [ADDRESS_229606] a6 weeks interval before m oving on to part 2 of 
the study (nivolumab monotherapy ).
If a participant in any of the nivolumab/ipi[INVESTIGATOR_193173], the participant shoul d discont inue both nivolumab and ipi[INVESTIGATOR_193174] .
Study  treatm ent shoul d be permanent ly discont inued for the fo llowing:
Any Grade 2 drug- related uveit is, ey e pain or bl urred visi on that does not respond to topi[INVESTIGATOR_186710] 1 severit y within the re -treatm ent peri od OR requi res 
systemic treatment
Any Grade 3 non -skin, drug -related adverse event lasting > 7 days, or recurs with the following 
exceptions for laboratory  abnorm alities, diarrhea, colitis, neurologic toxicity, drug-related 
Revised Protocol No.: 02
Date: 02-Aug-[ADDRESS_229607] ions, and endocrinopathies:
Grade [ADDRESS_229608] ion, or 
infusio n reaction of any duration requires discont inuat ion
Grade [ADDRESS_229609] acement. 
Grade 3 drug-related laboratory  abnorm alities do not require treatm ent discont inuat ion 
except:
Grade 3 drug-related thrombocytopenia > 7 days or associated with bleeding requires 
discontinuat ion
Any drug -related liver funct ion test (LFT) abnormalit y that meets the following criteria 
requi resdiscont inuat ion:
oGrade [ADDRESS_229610], ALT or Total Bilirubin requires discont inuat ion*
oConcurrent AST or ALT > [ADDRESS_229611] and total bilirubin > 2x ULN
* In most cases of Grade [ADDRESS_229612] or ALT elevati on, study  treatment (s) will be permanent ly 
discontinued. If the invest igator determines a possible favorable benefit/risk ratio that warrants 
continuat ion of study  treatment (s), a discussio n between the invest igator and the BMS Medical 
Moni tor/desi gnee m ust occur.
Any Grade 4 drug-related adverse event or laboratory  abnorm ality (including but not limited 
to creatinine , AST, ALT, or Total Bilirubin).
Any event that leads to delay in dosing lasting > 6weeks from the previous dose requires 
discontinuat ion, wi th the f ollowing ex cepti ons:
Dosing dela ys to allow for prolonged steroid tapers to manage drug- related adverse events 
are all owed. However, dosing must be discont inued for any drug rel ated AE that requi res 
treatm ent wi th 10mg/day  or greater prednisone or equivalent for more than 12 weeks.
Dosing delays lasting > 6 weeks from the previo us dose that occur for non-drug-related 
reasons may  be allowed if approved by  [CONTACT_102440]. 
Prior to re -initiating treatment in a participant with a dosing delay of >[ADDRESS_229613] igator, presents a substantial clinical risk to the participant with continued nivo lumab dosing.
7.4.4 Management Algorithms for Immu no-Oncology Agents
Immuno-oncol ogy (I-O) agents are associated with AEs that can differ in severit y and durati on 
than AEs caused by [CONTACT_53970] c classes. Nivo lumab, ipi[INVESTIGATOR_125], and BMS -986237 are 
Revised Protocol No.: 02
Date: 02-Aug-[ADDRESS_229614] investigators in assessing and managing the following groups of 
AEs:
Gastrointestinal
Renal
Pulmo nary
Hepati c
Endocrinopathy
Skin
Neurol ogical
Myocardi tis
The above algorithms are found in the Appendix 8of this protocol .
7.4.[ADDRESS_229615] ions should be graded according to NCI CTCAE 
(Versi on4.0) gui delines.
Treatment recommendations are provided below and may be modified based on local treatment 
standards and guidelines, as appropriate:
For Grade 1 symptoms: (mild reacti on; infusio n interruption not indicated; intervent ion not 
indicated):
Remain at bedside and monitor participant until recovery  from symptom s. The following 
prophylact ic prem edicati ons are recommended for future infusio ns: diphenhydramine 50 mg 
(or equivalent) and/or acetaminophen/p aracetam ol [ADDRESS_229616] 30 minutes before 
additional administrations .
For Grade 2 symptoms: (moderate reaction required therapy  or infusi on interrupti on but responds 
prom ptly to symptomat ic treatm ent [(eg, antihistamines, non-steroi dal anti-inflammatory  drugs, 
narcoti cs, corticosteroi ds, bronchodilators, IV fluids); prophylact ic med ications indicated for 
24hours) ]:
Stop the study  treatm entinfusio n, begin an IV infusio n of normal saline, and treat the 
participant with diphenhydramine 50mg IV (or equivalent) and/or 
acetaminophen/paracetamo l 325 to 1000 mg; remain at bedside and monitor participant until 
Revised Protocol No.: 02
Date: 02-Aug-2017 55
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
resol ution of symptoms. Corti costeroi d and/or bronchodilator therapy  may also be 
administered as appropri ate. If the infusio n is interrupted, then restart the infusio n at 50% of  
the original  infusi on rate when symptom s resolve; if no furth er complicat ions ensue after 
30minutes, the rate may be increased to 100% of the original  infusi on rate (for Arm B 
subjects ) or to 50% of the original infusio n rate ( for Arm A subjects ) until co mpletion of the 
infusio n. Moni tor participant closely. If  symptom s recur, then no further study  treatm entwill 
be administered at that visit .
For future infusio ns, the following prophylacti c prem edicat ions are recommende d: 
diphenhydramine 50 mg (or equivalent) and/or acetaminophen/paracetamo l [ADDRESS_229617] 30 minutes before infusio ns. If necessary , corti costeroi ds (up 
to 25 m g of hydrocorti sone or equivalent) may be used
For Grade 3 or 4 symptoms: (severe reacti on, Grade 3: prolonged [ie, not rapi[INVESTIGATOR_53892]/or brief interruption of infusion]; recurrence of symptoms fo llowing 
initial improvement; hospi [INVESTIGATOR_193175] (eg, renal impairment, 
pulmo nary infiltrates). Grade 4: Life -threatening; pressor or vent ilatory  support i ndicated):
Immediately discont inue infusio n of study  treatment . Begin an IV infusio n of normal saline 
and treat the participant as fo llows: Recommend broncho dilators, epi[INVESTIGATOR_238] 0.2 to 1 mg of a 
1:1000 solution for subcutaneous administration or 0.1 to 0.25 mg of a  1:10,000 solution 
injected slowly for IV administration, and/or diphenhydramine 50 mg IV with 
methylpredniso lone 100mg IV (or equivalent), as needed. Parti cipant shoul d be monitored 
until the Investigator is co mfortable that the symptoms will not recur. Study  treatm entwill be 
perm anent ly discont inued. Invest igators should follow their institutional guidelines for the 
treatm ent of anaphylaxis. Rema in at bedside and monitor participant until recovery of the 
symptoms
In case of late-occurring hypersensit ivity symptoms (eg, appearance of a l ocalized or generalized 
pruri tus within 1 week after treatm ent), symptomat ic treatment may be given (eg, oral 
antihistamine or corticosteroids).
7.5 Preparation/Handling/Storage/Accountability
The invest igational product shoul d be stored in a secure area according to local regulat ions. It is 
the responsibilit y of the investigator to ensure that invest igational product is only dispensed to 
study  Parti cipants. The invest igational product must be dispensed only fro m official study sites by 
[CONTACT_53971].
The product storage manager shoul d ensure that th e study  treatm entis stored in accordance with 
the environmental condi tions (temperature, light, and humidit y) as determined by [CONTACT_20444]. If 
concerns regarding the qualit y or appearance of the study  treatm entarise, the study treatm ent
shoul d not be di spensed and contact [CONTACT_186735].
Study  treatm entnot supplied by [CONTACT_53972].
Revised Protocol No.: 02
Date: 02-Aug-[ADDRESS_229618] documentation (whether supplied by [CONTACT_20447]) must be maintained that 
includes all processes requi red to ensure drug is accurately administered. This includes 
docum entati on of drug storage, administration and, as applicable, storage temperatures, 
reconstitution, and use of required processes ( e.g., requi red diluents, administration sets).
Further gui dance and information for final di sposi tion of unused study  treatment are provided 
in Appendix 2 and Study  Reference Manual .
 
 
 
 
 
 
7.6 Treatment Compliance
Treatment compliance will be monitored by [CONTACT_53973] y as well as the participant ’s 
medical record and electronic case report form (eCRF).
7.7.1 Prohibited and/or Restricted Treatmen ts
Prohibited and/or restricted medicat ions taken prior to study treatment administration in the study 
are described below. Medicat ions taken within [ADDRESS_229619] be recorded on the CRF.
The following medicat ions are prohibited during the study  (unless utilized to treat a drug related 
adverse event):
Immunosuppressive agents
Immunosuppressive doses of systemic corticosteroids (except as stated in Secti on 7.7.2 ).
Any concurrent anti -neopl astic therapy (ie, chemotherapy, hormonal therapy, immunotherapy, 
extensive, non -palliat ive radiati on therapy , or s tandard or invest igational agents for treatm ent 
of the di sease under study ). 
 
 
 
7.7.2 Permitted Therapy
Parti cipants are permitted the use of topi[INVESTIGATOR_2855], ocular, intra-articular, intranasal, and inhalat ional 
corticosteroi ds (with minimal systemic absorpti on). Adre nal replacement steroi d doses > 10 mg 
Revised Protocol No.: 02
Date: 02-Aug-2017 57
3.0
Approved
930107718
3.0
v

Clinical Protocol CA209800
BMS -936558 nivolumab
daily  prednisone are permitted. A brief (less than 3 weeks) course of corticosteroi ds for 
prophylaxis (eg, contrast dye allergy ) or for treatment of non-autoimmune condi tions (eg, 
delayed -type hypersensi tivity react ion caused by a contact [CONTACT_20435]) is permitted.
7.7.3 Other Restrictions and Precautions
Parti cipants with a condition requi ring systemic treatm ent with either corticosteroi ds (> 10 mg 
daily prednisone equivalent) or other immunosuppressive medicat ions within 14 days of treatment 
assignment are excluded. Inhaled or topi[INVESTIGATOR_8826], and adrenal replacement steroid doses 
> 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.
7.8 Treatment After the End of the Study
At the concl usion of the study , participant s who continue to demonstrate clinical benefit will be 
eligible to receive BMS supplied study  treatm entfor the maximum treatment duration specified in 
the protocol . Study  treatm entwill be provi ded via an extensio n of the study, a rollo ver study 
requi ring approval  by [CONTACT_186736] h authority  and ethics committee or through another 
mechanism at the discretion o f BMS.
BMS reserves the right to terminate access to BMS supplied study  treatmentifany of the fo llowing 
occur: a)the study  is terminated due to safet y concerns; b)the devel opment of nivolumab, 
ipi[INVESTIGATOR_125], and/or BMS -986237 is terminated for other reasons, including but not limited to lack 
of efficacy  and/or not m eeting the study  object ives; c) the participant can obtain medicat ion from 
a government sponsored or private health program . In all cases BMS will fo llow local regu lations
[ADDRESS_229620] (and non-invest igational product at the 
discreti on of  the invest igator) for any o f the following reasons:
Parti cipant’s request to stop study treatm ent.Participants who request to discontinue study 
treatm ent will remain in the study  and must continue to be followed for protocol specified 
follow-up procedures. The only  excepti on to this is when a participant specifically wit hdraws 
consent for any further contact [CONTACT_35859]/her or persons previously authorized by [CONTACT_53976] s informat ion
Any clinical adverse event (AE), laboratory  abnormalit y or intercurrent illness which, in the 
opi[INVESTIGATOR_3078] n of the invest igator, indicates that c ontinued participat ion in the study is not in the best 
interest of the participant
Terminat ion of the study  by [CONTACT_414] -Myers Squibb (BMS)
Loss of ability to freely  provide consent through imprisonment or involuntarily incarceration 
for treatm ent of ei ther a psychiatric or physical ( eg, infect ious di sease) illness.
Refer to the Schedule o f Activit ies for data to be collected at the time o f treatment discont inuat ion 
and fo llow-up and for any  further evaluat ions that can be co mpleted
Revised Protocol No.: 02
Date: 02-Aug-[ADDRESS_229621] immediately notify the BMS Medical 
Moni tor/desi gnee of this event In mo st cases, the study  treatm entwill be perm anently discont inued 
in an appropri ate manner (eg, dose tapering if necessary for participant safet y). Please call the 
BMS Medi cal Monitor within [ADDRESS_229622] igator 
determines a possible favorable benefit/risk rat io that warrants continuat ion of study  treatm ent, a 
discussio n between the invest igator and the BMS Medical Monitor/design ee m ust occur.
All participant s who discont inue study  treatm entshould comply wit h protocol specified fo llow-up 
procedures as outlined in Sect ion 2. The only  excepti on to this requi rement is when a participant
withdraws consent for all study  procedures including post -treatm ent study  follow-up or l oses the 
abilit y to consent freely  (ie, is imprisoned or invo luntarily incarcerated for the treatment of either 
a psy chiatri c or phy sical illness).
If study  treatm entis discontinued prior to the participant ’s co mpletion of the study , the reason for 
the discont inuat ion must be docum ented in the participant ’s medical records and entered on the 
appropriate case report form (CRF) page.
8.1.[ADDRESS_229623] ion of 
outcom e and/or survival follow-up data as required and in line with Section [ADDRESS_229624] that survival data be co llected on all treated/randomized participants outside o f 
the protocol  defined window. At the time of this request, each participant will be contact[CONTACT_193214]-up.
 
 
 
 
 
 
 
 
 
 
 
 
 
Revised Protocol No.: 02
Date: 02-Aug-2017 59
3.0
Approved
930107718
3.0
v

Clinical Protocol CA209800
BMS -936558 nivolumab
8.1.3 Treatment Beyond Disease Progression
Accumulat ing evidence indicates a minorit y of participant s treated with immunotherapy  may 
derive clinical benefit despi[INVESTIGATOR_193176].7
Parti cipants treated wi th study  treatm ent(s) will  be permi tted to continue treatm ent bey ond initial 
RECIST 1.[ADDRESS_229625] igator, as long as they 
meet the fo llowing cri teria:
Invest igator -assessed clinical benefit
Tolerance of study  treatm ent
Stabl e performance status
Treatment beyond progressi on will not delay an imminent intervent ion to prevent serious 
complicat ions of disease progressi on (eg, CNS m etastases)
Parti cipant provides written informed consent prior to receiving addit ional treatment. All other 
elements of the main consent including descripti on of reasonably foreseeable risks or 
discomforts, or other alternat ive trea tment opti ons will  still apply .
A radiographic assessment/ scan shoul d be perform ed within [ADDRESS_229626] igator feels that the participant continues to achieve clinical benefit by [CONTACT_193215], the participant shoul d remain on the tri al and continue to receive monitoring according 
to the Time and Events Schedule.
For the participant s who continue study therapy beyo nd progression, further progression is defined 
as an addit ional10% increase in tumor burden with a minimum 5 mm abso lute increase from t ime 
of initial PD. This includes an increase in the sum of diameters of all target lesions and/ or the 
diameters of new measurable lesio ns compared to the time of initial PD. Nivolum ab treatm ent 
shoul d be discont inued permanently upon documentation of further progression.
New lesions are considered measureable at the time of initial progressi on if the longest diameter 
is at least 10 mm (except for pathological lymph nodes which must have a short axis of at least 
15mm). Any new lesion considered non-measureable at the time of initial progressi on may 
beco me measureable and therefore included in the tumor burden if the longest diameter increases 
to at least 10 mm (except for pathological lymph nodes which must have a short axis of at least 
15mm). In situations where the relative increase in total tumor burden by 10% is solely  due to 
inclusio n of new lesions which beco me measurable, these new lesio ns must demonstrate an 
absolute increase of at least 5 mm .
Revised Protocol No.: 02
Date: 02-Aug-[ADDRESS_229627] with him/her or persons 
previously authorized by [CONTACT_53980]. 
Parti cipants shoul d notify  the investigator of the decisio n to withdraw consent from future 
follow-up in writing, whenever possible.
The withdrawal  of consent should be explained in detail in the medical records by [CONTACT_1275], as to whether the withdrawal is from further treatment with study  treatm entonly 
or also from study  procedures and/or post treatment study  follow-up, and entered on the 
appropriate CRF page.
Asvital status (whether the participant is alive or dead) is being measured, publicly  available 
inform ation shoul d be used to determine vital status only as appropri ately directed in 
accordance with local law.
If the participant withdraws consent for disclosure of future informat ion, the sponsor may 
retain and cont inue to use any data collected befor e such a withdrawal o f consent.
8.[ADDRESS_229628] to Follow -Up
All reasonable efforts must be made to locate participant s to determine and report their ongoing 
status. This includes fo llow-up wi th persons authorized by  [CONTACT_2299] .
Lost to follow -up is defined by  [CONTACT_186743] a mini mum o f three
docum ented phone calls, faxes, or emails as well as lack of response by [CONTACT_53982] m ail letter. All attempts should be documented in the participant’s medical records.
If it is determined that the participant has died, the site will use permissible local methods to 
obtain date and cause of death.
If invest igator’s use o f third-party  representative to assist in the fo llow-up porti on of the study 
has been included in the partici pant’s informed consent, then the investigator mayuse a 
Sponsor retained third-party  representative to assist site staff with obtaining participant’s 
contact [CONTACT_53983]-up 
porti on of  the study . 
The si te staff  and representative will con sult publicly available sources, such as public healt h 
registries and databases, in order to obta in updated contact [CONTACT_3031].
If after all attempts, the participant remains lost to fo llow-up, then the last known alive date as 
determined by [CONTACT_53984]’s medical 
records.
9 STUDY ASSESSMENTS AN D PROCEDURES
Study  procedures and timing are summarized in the S chedule of Activities. 
Protocol  waivers or exempt ions are not allowed .
Revised Protocol No.: 02
Date: 02-Aug-2017 61
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
All immediate safet y concerns must bediscussed with the Sponsor immediately upon 
occurrence or awareness to determine if the participant should continue or discontinue 
treatm ent.
Adherence to the study  design requi rements, including those specified in the Schedule of 
Activities, is essenti al and requi red for study  conduct.
All screening evaluat ions must be completed and reviewed to confirm that potential 
participants m eet all eligibilit y criteria before randomizat ion. The invest igator will maintain a 
screenin g log to record details of all participants screened and to confi rm eligibili ty or record 
reasons for scr eening failure, as applicable.
Procedures conducted as part of the participant’s routine clinical management (eg, blood count) 
and obtained before signing of inform ed consent may be utilized for screening or baseline 
purposes provided the procedure meets the protocol -defined criteria and has been performed 
within the t imeframe defined in the S chedule of Activit ies.
Addit ional measures, including non-study required laboratory  tests, shoul d be performed as 
clinically indicated or to com ply with local regulati ons. Laboratory  toxicities (eg, suspected drug 
induced liver enzyme evaluat ions) will be monitored during the follow-up phase via on si te/local 
labs until all study  treatm entrelated toxicities resolve, return to baseline, or are deemed 
irreversible.
If a participant shows new or worsening cardiac -related signs, symptoms, or findings (eg, dyspnea 
at rest/on exert ion, heart block, cardi omyopathy  or reduc ed LV function on imaging) consistent  
with possible cardi ac adverse events, the participant should be immediately evaluated to rul e out 
myocardi tis toxicity, according to the suspected Myotoxicity (myositis, myocardi tis, 
rhabdo myolysis) adverse event management algorithm in the BMS -936558 (nivo lumab) 
Invest igator Brochure.
Some of the assessments referred to in this sect ion may not be captured as data in the eCRF. They 
are intended to be used as safet y monitoring by [CONTACT_173359]. Addit ional testing or 
assessments may be perform ed as clinically  necessary  or wh ere required by [CONTACT_186745].
9.[ADDRESS_229629] -enhanced computed tomography  (CT) scans acqui red on 
dedicated CT equi pment i s preferred for this study . Contrast -enhanced CT of the chest, abdomen, 
pelvis, and other known/suspected sites of disease should be performed for tumor assessments. 
Shoul d a participant have contraindicat ion for CT intravenous contrast, a non-contrast CT of  the 
chest and a contrast -enhanced MRI of the abdomen, pelvis, and other known/suspected sites of 
disease shoul d be obtained. A contrast -enhanced MRI of the chest may be obtained instead of a 
non-contrast CT of the chest.
Revised Protocol No.: 02
Date: 02-Aug-[ADDRESS_229630] MRI of the abdo men, pelvis, and other 
known/suspected sites of disease should be obtained. A non -contrast MRI of the chest, abdom en, 
pelvis, and other known/suspected sites of disease is also acceptable.
Shoul d a participant have contraindicat ion for MRI (eg, incompat ible pacemaker) in addition to 
contraindicat ion to CT i ntravenous contrast, a non -contrast CT of the chest, abdomen, pelvis, and 
other known/suspected s ites of disease is acceptable.
CT and MRI scans shoul d be acqui red with slice thickness of 5 mm or less with no intervening 
gap (contiguous). Every  attempt should be made to image each participant using an ident ical 
acquisit ion protocol  on the same scanner for all imaging timepo ints. 
For participants with known/suspected brain metastasis, a brain MRI without and with contrast 
(preferred) or a head CT without and with contrast is required at screening to rule out active brain 
metastasis. Parti cipant s with a history  of brain metastasis should have surveillance MRI/CT 
approximately  every [ADDRESS_229631] v1.1 criteria (see Appendix 5) until disease progressi on per RECIS T v1.1 criteria (see 
Appendix 5)or treatm ent discont inuation, whichever occurs later .
Tumor assessments at other tim epoints may be performed if clinically  indicated. Assessments of 
PR and CR must be confirmed at least [ADDRESS_229632] igators will also report the number and size of new lesions that appear while on 
study . The timepo int of tumor assessments will be reported on the eCRF based on the 
investigator’s assessment using RECIST v1.1 criteria. (See Appendix 5for specifics of 
RECIST v1.1 criteria to be utilized in this study.)
For participants who are treated beyond RECIST v1.1 defined progressi on, assessment will be
perform ed unt il discont inuat ion of study treatment (typi[INVESTIGATOR_193177] 10% or 
greater increase in tum or burden vol ume from the time of initial progressi on [including all  target 
lesions and new measurable lesio ns]). 
9.1.1 Imaging Assessment for the Study
Central  assessments are not planned for thi s study .  However, copi[INVESTIGATOR_014] o f all scans will be stored at 
sites for possible future analysis. At the Sponsor’s discretion, scans may be collected for possible 
future analysis if determined to be neces sary by [CONTACT_193216]. 
9.2 Adverse Events
The definit ions of an AE or serious adverse event (SAE) can be found in Appendix 3.
AEs will be reported by [CONTACT_2299] (or, when appropriate, by a caregiver, surrogate, or the 
participant's legally  authori zed r epresentative). 
Revised Protocol No.: 02
Date: 02-Aug-[ADDRESS_229633] igator and any designees are responsible for detecting, docum enting, and reporting 
events that meet the definit ion of an AE or SAE and remain responsible for following up AEs that 
are serious, considered related to the study trea tment or the study , or that caused the participant to 
discontinue before complet ing the study. 
Immune-mediated adverse events are AEs consistent with an immune -mediated mechanism or 
immune -mediated component for which non-inflammatory  etiologies (eg, infection or tumor 
progression) have been ruled out. IMAEs can include events with an alternate etio logy which were 
exacerbated by [CONTACT_53995] y. Inform ation supporting the assessment will be 
collected on the participant’s case report form.
Contacts for SAE reporting specified in Appendix [ADDRESS_229634] dose of study therapy, at the timepo ints specified in the Schedule of 
Activities (Section 2). Non-serious AE informat ion shoul d also be collected from the start of a 
placebo l ead-in period or other observat ional perio d intended to establish a baseline status for the 
participants .
Secti ons 5.6.1 and 5.6.2 in the Investigator Brochure (IB) represent the Reference Safet y 
Inform ation to determine expectedness of serious adverse events for expedited reporting. 
Following the participant’s written consent to pa rticipate in the study , all SAEs, whether related 
or not rel ated to study  treatment , must be collected, incl uding those thought to be associ ated wi th 
protocol -specified procedures.
All SAEs must be collected that occur during the screening period and within [ADDRESS_229635] 
dose of study treatment. For participants randomized/assigned to treatment and never treated with 
study  treatm ent, SAEs should be co llected for 30 days from the date of rando mizat ion.
Admissio n for administration of anticancer therapy in the absence of any ot her SAEs (applies to 
oncol ogy protocols)
Invest igators are not obligated to actively seek AEs or SAEs in former study  participants. 
However, if the invest igator learns of any SAE, including a death, at any time after a participant 
has been discharged fro m the study, and he/she considers the event reasonably related to the study 
treatm ent or study  parti cipat ion, the invest igator must prompt ly notify the sponsor.
The method of evaluat ing, and assessing causality  of AEs and SAEs and the procedures for 
completing and reporting/ transmi tting SAE reports are provided in Appendix 3.
9.2.[ADDRESS_229636] ioning, 
examinat ion, or evaluation o f a participant . (In order to prevent reporting bias, participant s should 
not be questioned regarding the specific occurrence of one or more AEs.)
Revised Protocol No.: 02
Date: 02-Aug-2017 64
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
9.2.3 Follow -up of AEs and SAEs
Nonserious AEs shoul d be followed to resol ution or stabilizat ion, or reported as SAEs if they 
beco me serious (see Section Appendix 3).
Follow-up is also requi red for nonserious AEs that cause interruption or discont inuation of 
study  treatm ent and for those present at the end of study treatment as appropriate.
 All ident ified nonserious AEs must be recorded and described on the nonseri ous AE page of 
the CRF (paper or electronic). Com pletion of supplemental  CRFs may be requested for AEs 
and/or laboratory  abno rmalities that are reported/ident ified during the course of the study .
After the init ial AE/SAE report, the invest igator is required to proactively fo llow each parti cipant 
at subsequent visits/contacts. All SAEs, and non-serious AEs of special interest will be followed 
until resolution, until the condi tion stabilizes, until the event is otherwi se explained, or until the 
participant is l ost to foll ow-up (as defined in Section 8.3).
Further informat ion on fo llow-up procedures i s given in Appendix 3.
9.2.4 Regulatory Reporting Requirements for SAEs
Prom pt notificat ion by [CONTACT_193217] y of participants and the safet y of a 
product under clinical investigation are met.
An invest igator who receives an invest igator safety report describing SAEs or other specific 
safet y information (eg, summary  or listing of SAEs) from the Sponsor will file it along with 
the Invest igator’s Brochure and will notify  the IRB/IEC, if appropri ate according to local 
requi rements.
Sponsor or designee will be reporting adverse events to regulatory authori ties and ethics 
committees according to local applicable laws including European Directive 2001/20/EC and FDA 
Code of Federal Regulat ions 21 CFR Parts 312 and 320. A S[LOCATION_003]R (Suspected, Unexpected 
Serious Adverse Reacti on) is a subset of SAEs and wil l be reported to the appropri ate regul atory 
authori ties and invest igators fo llowing l ocal and global  guidelines and requi rements.
9.2.[ADDRESS_229637] immediately notify the BMS 
Medical Monitor/designee of this event and complete and forward a Pregnancy Surveillanc e Form 
to BMS Designee within [ADDRESS_229638] cases, the study  treatm entwill be permanent ly discont inued in an appropriate manner ( eg, 
dose tapering if necessary  for participant safety). Please call the BMS Medical Moni tor within 
24hours of awareness of the pregnancy.
Revised Protocol No.: 02
Date: 02-Aug-[ADDRESS_229639] resul t abnorm alities shoul d be captured on the nonseri ous AE CRF 
page or SAE Report Form  electronic ,as appropri ate. Paper f orms are only intended as a back-up 
option when the el ectronic system is not functioning.
Any laboratory  test res ult that is clinically significant or meets the definit ion of an SAE 
Any laboratory  test resul t abnormalit y that required the participant to have study  treatm ent
discontinued or interrupted
Any laboratory  test resul t abnormalit y that required the participant to receive specific 
corrective therapy
It is expected that wherever possible, the clinical rather than laboratory term would be used by [CONTACT_53999] ( eg, anemia versus low hemoglobin value).
9.2.7 Potential Drug Induced Liver Injury (DILI)
Wherever possible, timely confi rmation of initial liver-related laboratory  abnormalit ies shoul d 
occur prior to the reporting of a potential DILI event. All occurrences of potential DILIs, meet ing 
the defined criteria, must be reported as SAEs (see Appendix 3 for reporting details).
Potenti al drug induced liver injury  is defined as: 
1) AT (ALT or AST) elevation > 3 times upper limit of normal (ULN), AND;
2)Total  bilirubin > [ADDRESS_229640], wit hout init ial findings o f cholestasis (elevated serum alkaline 
phosphatase ), AND;
3)No other immediately apparent possible causes of AT elevat ion and hyperbilirubinemia, 
including, but not limi ted to, vi ral hepatitis, pre-exist ing chronic or acute liver disease, or the 
administration of other drug(s) known to be hepatotoxic.
9.2.8 Othe r Safety Considerations
Any significant worsening noted during interim or final physical examinat ions, x-ray filming, any 
other potential safety assessment required or not required by [CONTACT_20492] a 
nonseri ous or seri ous AE, as appro priate, and reported accordingly.
Revised Protocol No.: 02
Date: 02-Aug-[ADDRESS_229641] be reported as SAEs (see Appendix 3 ).
In the event of an overdose the invest igator/treating physician shoul d:
1)Contact [CONTACT_27465]
2)Closely  monitor the parti cipant for AEs/SAEs and laboratory  abnorm alities
3)Docum ent the quantit y of the excess dose as well as the duration of the overdosing in the CRF.
Decisio ns regarding dose interruptions or modificat ions will be made by [CONTACT_32844] h the Medical Monitor based on the clinical evaluat ion of the participant.
9.[ADDRESS_229642] ivities.
9.4.3 Clinical Safety Laboratory Assessments
Invest igators must document their review of each laboratory  safety  report.
All clinical safet y laboratory  assessments will be performed locally per the Schedule of 
Activities an dTable 9.4.3 -1.
Table 9.4.3 -1: Laboratory Assessment Panels
Hematology
Hemoglobin
Hematocrit
Total leukocyte count, including differential
Platelet count
Serum Chemistry
Aspartate aminotransferase (AST)
Alanine aminotransferase (ALT)
Total bilirubin
Alkaline phosphatase
Creatinine
Blood Urea Nitrogen (BUN) or Serum Urea Level
GlucoseTotal Protein
Albumin
Sodium
Potassium
Chloride
Calcium
Phospho rus
Revised Protocol No.: 02
Date: 02-Aug-2017 67
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
Table 9.4.3 -1: Laboratory Assessment Panels
LDH
Corrected CalciumTSH (reflex to free T3 and T4 if abnormal)
Lipase
Amylase
Creatinine clearance (CLcr) -(screening only)
Serology
Serum for hepatitis C antibody, hepatitis B surface antigen, HIV -1 and -2 antibody (screening only)
Other Analyses
Pregnancy test (WOCBP only, as described in Section 2).
9.4.[ADDRESS_229643] m edical/clinical judgment. 
9.[ADDRESS_229644] prior to the delayed dose. However, if a predose sample 
is collected but the dose is subsequent ly delayed, an addit ional predose sample shoul d not be 
collected. Further details of sample collection, processing, and shipment will be provided in the 
laboratory  procedures m anual .
Blood sam ples shoul d be drawn from a site other than the infusio n site (ie, contralateral arm) on 
days of infusio n. All samples collected pre-dose should be taken just prior to th e administratio n 
from the contralateral arm (ie, the arm not used for the infusio n). If the infusio n was interrupted, 
the interruption details will also be documented on the CRF. Blood samples will be processed to 
collect serum  and stored preferably at -70°C (sampl es may be stored at -20°C up to 2months). 
Further details of pharmacokinet ic sample co llection and processing will be provided to the site in 
the lab m anual.
Serum  samples will be analyzed for drug (nivolumab and ipi[INVESTIGATOR_125]) and ADA (anti -nivolumab 
and anti-ipi[INVESTIGATOR_193178])by [CONTACT_143941]. Samples with a  positive ADA 
response may also be analyzed for neutralizing ADA response to nivo lumab and/or ipi[INVESTIGATOR_125]. 
In addition, selected serum samples may be analyzed by [CONTACT_193218][INVESTIGATOR_125], or detect anti-drug antibodies for techno logy explorat ion purposes; 
exploratory  results will not be reported. The corresponding serum  samples designated for either 
PK, immunogenicit y or biomarker assessments may also be used for any of those analyses, if 
requi red (eg, insufficient sample volume to complete testing or to follow up on suspected 
immunogenicit y related AE).
Revised Protocol No.: 02
Date: 02-Aug-2017 68
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
Table 9.5-1: Pharmacokinetic and Immunogenicity Sample Collections (CA209800 Arms A and B)
PartaStudy Dayb
( 1 Cycle = 3 weeks for Part 1
1 Cycle = 4 Weeks for Part 2)Time (Event)
Time (Relative to 
Start of Infusion) 
Hours:Min
Pharmacokinetic 
Blood Sample for 
Nivolumab
Immunogenicity 
Blood Sample for 
Nivolumab
Pharmacokinetic 
Blood Sample for 
Ipi[INVESTIGATOR_193179]
1 C1D1 (Predose)c00:00 X X X X
1 C1D1 (EOI -nivo)d00:60 X
1 C1D1 (EOI -ipi)d00:60 or 00: 30 X
1 C2D1 (Predose)c00:00 X X X X
1 C2D1 (EOI -nivo)d00:60 X
1 C2D1 (EOI -ipi)d00:60 or 00: 30 X
1 C4D1 (Predose)c00:00 X X X X
1 C4D1 (EOI -nivo)d00:60 X
1 C4D1 (EOI -ipi)d00:60 or 00: 30 X
2 C5D1 (predose) 00:00 X X X X
2CXD1: Every 16 weeks starting with 
C5D1 (ie, C9D1, C13D1, etc.)(Predose) 00:[ADDRESS_229645] 2 Follow -up Visits (Approximately 
30 days and up to ~ 100Days from the 
Discontinuation of Study treatment )NA X X
aPart [ADDRESS_229646] 12 weeks (or 4 cycles) of combination treatment (nivolumab + ipi[INVESTIGATOR_125]). Part 2 indicates nivolumab monotherapy period starting from 
Week 16 (or Cycle 5).
bIf a participant discontinues study treatment treatment during the sampling period, they will move to sampling at the follow -up visits.
cPredose: All pred ose samples for nivolumab and ipi[INVESTIGATOR_193180].
dEOI- nivo and EOI- ipi [INVESTIGATOR_193181]: End of Infusio n PK samples for nivolumab and ipi[INVESTIGATOR_125], respectively. For sequential dosing, EOI samples for 
nivolumab and ipi[INVESTIGATOR_193182] (preferably within 2 -5 minutes) prior to the end of the 60 minute nivolumab infusion and 
30 minutes ipi[INVESTIGATOR_182], respectively. For the FRC dosing, EOI samples for nivolumab and ipi[INVESTIGATOR_193183] y 
Revised Protocol No.: 02
Date: 02-Aug-2017 69
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
(preferably within 2 -5 minutes) prior to the end of the 60 min FRC co -infusion. If the end of any  infusion is delayed, the coll ection of the EOI samples 
should be delayed accordingly.
Revised Protocol No.: 02
Date: 02-Aug-[ADDRESS_229647] ion and shipment of these samples can be found in Secti on9.8.
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revised Protocol No.: 02
Date: 02-Aug-2017 71
3.0
Approved
930107718
3.0
v

Clinical Protocol CA209800
BMS -936558 nivolumab
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revised Protocol No.: 02
Date: 02-Aug-2017 72
3.0
Approved
930107718
3.0
v

Clinical Protocol CA209800
BMS -936558 nivolumab
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9.9 Medical Resource Utilization and Health Economics
Evaluat ing qualit y of life (QoL) in oncol ogy clinical studi es is beco ming increasingly important 
to understand the impact of benefi t/risk from the participant perspective. Parti cipant reported 
outcom es will be captured through the use of three validated self-reported questionnaires: the 
Funct ional Assessment of Cancer Therapy -General (FACT -G), the NCCN Funct ional Assessment  
of Cancer Therapy -Kidney Symptom  Index (FKSI -19) and the EuroQoL Group’s EQ-5D 
(3Lversio n).
The FACT -G is a [ADDRESS_229648] ions divided into four primary HrQoL dimensio ns: Physical Well -Being, 
Social/Family Well -Being, Emotional Well -Being, and Funct ional Well -Being. Summary scores 
can be calculated for each domain in addit ion to a single overall summary score. 
Revised Protocol No.: 02
Date: 02-Aug-2017 73
3.0
Approved
930107718
3.0
v

Clinical Protocol CA209800
BMS -936558 nivolumab
The NCCN FKSI -19 is a 19-item scale that measures tumor specific HrQoL in kidney cancer 
participant s. The FKSI -19 uses five Likert -type response categories that range fro m “not at all” to 
“very much”. Parti cipant s are asked to circle the response category  that best characterizes their 
response over the last 7 days on 19 items that include symptom s such as lack of energy, fatigue,  
appeti te, coughing, shortness of breath, pain, nausea and abilit y to work. General healt h status will 
be measured using the EQ- 5D.
The EQ -5D is a standardized instrument for use as a measure of self -reported general healt h status. 
The EQ-5D comprises 5 dimensio ns (mobility, self-care, usual activities, pain/disco mfort, and 
anxiet y) and a visualanalog rating scale (VAS). The utilit y data generated from the EQ-5D is 
recommended for and commo nly used in cost effectiveness analysis.
Healthcare resource utilizat ion data (eg, hospi[INVESTIGATOR_602], non-protocol  specified medical visits, 
etc.) will be collected for all rando mized participant s. Specifically, healthcare resource utilizat ion 
is evaluated based on the number of medical care encounters such as hospi[INVESTIGATOR_193184], outparticipant visits, diagnosti c tests and procedures, concomitant medications and 
reasons for the en counters. 
Medical resource utilizat ion associ ated with medical encounters, will be collected in the CRF by 
[CONTACT_193219] -site personnel  for all participants throughout the study . 
Protocol -mandated procedures, tests, and encounters are excluded. 
The data collected may be used to conduct exploratory  economic analyses and will include:
Number and durati on of medical  care encounters, including surgeri es, and other selected 
procedures (in participant and out participant )
Durati on of hospi[INVESTIGATOR_3094] (total days length of stay, including durati on by [CONTACT_54006]; eg, intensive 
care unit)
Number and character of diagnostic and therapeutic tests and procedures
Outparticipant medical encounters and treatm ents (including physician or emergency room 
visits, tests and procedures, and medicat ions)].
10 STATISTICAL CONSIDER ATIONS
10.1 Sample Size Determination 
Approximately 102 participant s will be randomized to the 2 treatment arms in a 1:1 ratio in order 
to target 100 treated participant s (50 per arm ). This number of treated participant s was chosen to 
achieve a sufficient level of precisi on for estimating the difference in rates of infusi on-related 
reacti ons between the two treatment arms. Fift y treated participant s per arm will allow est imatio n 
of the rate difference wit hin 95% confidence limits of -20% or less and will be supplemented by 
a qualitat ive clinical assessment of the type and severit y of events to evaluate benefit -risk.The 
20% limit represents what is considered to be a clinically meaningful difference in the rates of 
infusio n-related reacti ons.
Revised Protocol No.: 02
Date: 02-Aug-2017 74
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
In previously submi tted Phase 2/3 studi es of nivolumab in combinat ion with ipi[INVESTIGATOR_162] b 
(CA209069 and CA209067), AEs in the MedDRA Anaphylact ic React ion SMQ (broad scope) 
with onset within 2 days after sequent ial dosing of nivo lumab 1 m g/kg co mbined with ipi[INVESTIGATOR_125] 
3mg/kg were reported in 24% of treated participant s. In the current stu dy, if the observed rate of 
infusio n reactions is equal to 24% among 50 treated participant s in each arm, then the 95% CI for 
the difference in rates of infusio n reactions between arms will be ( -16.7%, 16.7%).
Table 10.1-1shows the precisio n that the sample size of 50 treated participant s per arm will 
provi de for estimating infusio n reacti on rates and rate differences between the treatm ent arms 
under different assum ed observed rates.
Table 10.1-1: 95% CI for Rates and Rate Differences when Observed in 
50Participant s per Arm
Observed AE Rate (95% CI) Observed Rate Difference (95% CI)
Arm A (Co -administration, FRC)Arm B (Sequential 
administration)Arm A -Arm B
24% (13.1%, 38.2%) 22% (11.5%, 36.0%) 2% ( -14.5%, 18.5%)
24% (13.1%, 38.2%) 24% (13.1%, 38.2%) 0% ( -16.7%, 16.7%)
26% (14.6%, 40.3%) 24% (13.1%, 38.2%) 2% ( -15.0%, 19.0%)
30% (17.9%, 44.6%) 28% (16.2%, 42.5%) 2% ( -15.8%, 19.8%)
30% (17.9%, 44.6%) 30% (17.9%, 44.6%) 0% ( -18.0%, 18.0%)
10.[ADDRESS_229649] (primary ) analysis will  be carri ed out f or primary  endpoint and safet y related secondary 
endpo intswhen all participants who are still on-treatment complete Part [ADDRESS_229650] ive will be addressed by  a saf ety endpo int, the primary  endpoint analysis 
will be based on all treated participant s. For consistency, the secondary  endpo ints will use the same 
analysis population as the primary endpoint ( ieall treated participant s).
Population Description
All Enrolled Parti cipant s All participant s who si gned an informed consent form and were 
registered into the IRT. 
All Rando mized 
Parti cipants All participant s who were randomized to any  treatment group. 
This is the primary dataset for efficacy  listings.
All Treated Participant s All participant s who received at least one dose of any study  
medicat ion. This is the primary dataset for analysis of study  
conduct, study  popul ation, efficacy  (including secondary  
endpo ints), exposure, and safet y (including primary endpo int).
Revised Protocol No.: 02
Date: 02-Aug-[ADDRESS_229651] evaluable tumor assessment prior to the 
Revised Protocol No.: 02
Date: 02-Aug-[ADDRESS_229652] at least9 months o f follow-up. Descri ptive 
analyses o f secondary  efficacy endpoints will be performed.
ORRs and corresponding 95 % exact CIs will be calculated using the Clopper 
Pearson m ethod for each of the treatment arms. BOR will be tabulated for 
each treatment group. Associated odds ratios and 95% CIs for Arm A relative 
to Arm  B will be calculated using Cochran -Mantel -Haenszel (CMH) 
methodol ogy, adjusting for the stratificat ion factors IMDC scores at 
screening. An est imate of the difference in ORRs and corresponding 2 -sided 
95% CI will be calculated using CMH methodology, adjusting for the same 
stratificat ion factors as above.
PFS curves for each treatment group will be estimated using the Kaplan -
Meier (KM) product limit method. Median PFS and corresponding two -sided, 
95% confidence intervals will be co mputed. Descriptive HRs and 
corresponding two sided 95% CIs for Arm A relative to Arm  B will  be 
estimated using a Cox proportional hazards model, with treatment group as a 
single covariate, stratified by [CONTACT_193220]. PFS rates at 6 
months wit h 95% CIs will be est imated using KM methodology.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revised Protocol No.: 02
Date: 02-Aug-[ADDRESS_229653] scope SMQ with onset on the day  of or wi thin 
2days after any  study  therapy  infusi on during the combinat ion peri od (Part 1) 
divided by [CONTACT_193221]. The analysis o f the primary 
endpo int will occur at the time of first (primary) analysis when all participants 
who are still on -treatm ent have had at l eastcomplete Part [ADDRESS_229654] ion SMQ occurring within 2 days after any dose in Part 1 
dosing by  [CONTACT_3219] , the difference in rates between arms, and the 
corresponding 95% confidence intervals will be reported descriptively. The 
confidence inter vals for the rate estimates will be based on the Clopper and 
Pearson m ethod. The estimate and confidence interval for the rate difference 
will be based on CMH method of weight ing, adjusting for IMDC scores at 
screening. Descript ive statist ics will be prese nted using NCI CTCAE v 4.[ADDRESS_229655] ion narrow scope SMQ occurring within 2 days after any  
study  therapy  infusi on during the combinat ion period (Part 1). This incidence 
rate will be defined similarly to the primary endpo int except that the event 
rate will be based on terms wit hin the narrow scope SMQ rather than the 
broad scope.
The second secondary  endpoint i s the drug -related Grade 3 -5 AE incidence 
rate defined using NCI CTCAE v 4.0 criteria. The drug -related Grade 3 - 5 
Revised Protocol No.: 02
Date: 02-Aug-[ADDRESS_229656] 
(primary) analysis when all participants who are still on -treatm ent complete 
Part [ADDRESS_229657] ic Reaction SMQ based on 
MedDRA versio n 19.0 are listed in Table 10.3.2 -1.
Revised Protocol No.: 02
Date: 02-Aug-2017 79
3.0
Approved
930107718
3.0
v

Clinical Protocol CA209800
BMS -936558 nivolumab
Table 10.3.2-1: Preferred Terms Included in the MedDRA Anaphylactic Reaction 
SMQ -Broad and Narrow Scopes
Preferred Term Term Scope
Acute respi[INVESTIGATOR_193185] n Narrow
Anaphy lactoid reaction Narrow
Anaphy lactoid shock Narrow
Angioedema Broad
Asthma Broad
Blood pressure decreased Broad
Blood pressure diastolic decreased Broad
Blood pressure systolic decreased Broad
Bronchial oedema Broad
Bronchospasm Broad
Cardiac arrest Broad
Cardio -respi[INVESTIGATOR_193186] -respi[INVESTIGATOR_193187].: 02
Date: 02-Aug-2017 80
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
Table 10.3.2-1: Preferred Terms Included in the MedDRA Anaphylactic Reaction 
SMQ -Broad and Narrow Scopes
Preferred Term Term Scope
Hyperventilation Broad
Hypotension Broad
Injection site urticaria Broad
Irregular breathing Broad
Kounis syndrome Narrow
Laryngeal dy spnoea Broad
Laryngeal oedema Broad
Laryngospasm Broad
Laryngotracheal oedema Broad
Lip oedema Broad
Lip swelling Broad
Mouth swelling Broad
Nasal obstruction Broad
Nodular rash Broad
Ocular hy peraemia Broad
Oedema Broad
Oedema mouth Broad
Orophary ngeal spasm Broad
Orophary ngeal swelling Broad
Periorbital oedema Broad
Pruritus Broad
Pruritus allergic Broad
Pruritus generalised Broad
Rash Broad
Rash erythematous Broad
Rash generalised Broad
Rash pruritic Broad
Respi[INVESTIGATOR_193188].: 02
Date: 02-Aug-2017 81
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
Table 10.3.2-1: Preferred Terms Included in the MedDRA Anaphylactic Reaction 
SMQ -Broad and Narrow Scopes
Preferred Term Term Scope
Stridor Broad
Swelling Broad
Swelling face Broad
Swollen to ngue Broad
Tachy pnoea Broad
Throat tightness Broad
Tongue oedema Broad
Tracheal obstruction Broad
Tracheal oedema Broad
Type I hy persensitivity Narrow
Upper airway obstruction Broad
Urticaria Broad
Urticaria papular Broad
Wheezing Broad
[IP_ADDRESS] Pharmacokinetic Analyses as a Secondary Endpoint
One of the secondary  endpo int is to get PK comparisons of nivolumab and ipi[INVESTIGATOR_193189]. PK will be 
measured using serum concentration -time data.
PK com parisons will be summarized using descri ptive summary statis tics to com pare nivolumab 
and ipi[INVESTIGATOR_193190].
[IP_ADDRESS] Other Pharmacokinetic Analyses
The nivo lumab and ipi[INVESTIGATOR_193191] t ime data obtained in th is study may be combined 
with data from other studi es in the clinical developm ent program to develop a populat ion PK 
model, if needed, to com pare model based PK param eters and exposure foll owing administrati on 
of the FRC and sequent ial administrati on. This model will be used to determine measures of 
individual exposure (such as steady  state peak, trough and time- averaged concentrati on). If 
conducted, the results of the populat ion PK analyses will be reported separately.
 
Revised Protocol No.: 02
Date: 02-Aug-2017 82
3.0
Approved
930107718
3.0
v

Clinical Protocol CA209800
BMS -936558 nivolumab
[IP_ADDRESS] Outcomes Research Analyses
Descript ive summary statistics of Quali ty of life (QoL) assessments will be presented at baseline 
and each on -study  time point, unless otherwise specified. Mean changes fro m baseline for each o f 
the three scales will be calculated for each subject at each on -study  time point. In addit ion, subject 
compliance will  be described per time point by  [CONTACT_193222] f illed out the QoL 
assessments over the numbers of subject known to be alive and eligible for assessment at these 
time points.
[IP_ADDRESS] Other Analyses
Methodol ogy for other analyses including pharmacogenomics, immunogenicit y, and healthcare 
resource utilizat ion is described in the statistical analysis plan finalized before database lock.
[IP_ADDRESS] Interim Analyses
Not applicable.
Revised Protocol No.: 02
Date: 02-Aug-2017 83
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
12 APPENDICES
Revised Protocol No.: 02
Date: 02-Aug-[ADDRESS_229658] aspartate aminotransferase
AT aminotransaminases
AUC area under the concentration -time curve
AUC(INF) area under the concentration -time curve from t ime zero extrapolated to 
infinite t ime
AUC(0 -T) area under the concentration -time curve from  time zero to the time of the 
last quantifiable concentration
AUC(TAU) area under the concentration -time curve in one dosing interval
A-V atrioventri cular
-HCG beta-human chorionic gonadotrophin
BID, bi d bis in die, twice daily
BLQ below limit of quant ification 
BMI body  mass index
BMS Bristol-Myers Squibb
BP blood pressure
BUN blood urea nitrogen
C Celsius
Ca++ calcium
Cavg average concentration
CBC complete bl ood count
Cexpected- tau expected concentration in a dosing interval
CFR Code of Federal Regulat ions 
CI confidence interval
C1- chloride
Revised Protocol No.: 02
Date: 02-Aug-2017 88
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
Term Definition
CLcr creatinine clearance
cm centimeter
Cmax, CMAX maximum observed concentration
Cmin, CMIN minimum observed concentration
CNS Central  nervous system
CRC Clinical Research Center
CRF Case Report Form, paper or electronic
Ctrough Trough observed plasma concentration
CV coefficient of variat ion
CYP cytochrom e p-450
D/C discontinue
dL deciliter
DMC Data m onitoring committee
DSM IV Diagnostic and Stati stical Manual of Mental Disorders (4thEdition)
EA extent of absorption
ECG electrocardi ogram
eCRF Electronic Case Report Form
EDC Electronic Data Capture
EEG electroencephalogram
eg exempli gratia (for example)
ESR Expedited Safet y Report
F bioavailabilit y
FDA Food and Drug Administration
FSH follicle stimulat ing horm one
FRC Fixed Rat io Com binat ion
g gram
GC gas chro matography
GCP Good Clinical Pract ice
GGT gamma- glutamyl  transferase
GFR glomerular filtrat ion rate
Revised Protocol No.: 02
Date: 02-Aug-[ADDRESS_229659] (that is)
IEC Independent Ethics Committee
IMP investigat ional medicinal products
IND Invest igational New Drug Exempt ion
IRB Institutional Review Board
IRT Interactive Response Techno logy
IU International Unit
IV intravenous
K slope of  the terminal phase of the log concentration -time curve
K3EDTA potassi um ethylenediaminetetraacetic acid
K+ potassi um
kg kilogram
L liter
LAM Lactati on amenorrhea m ethod
LC liquid chro matography
LDH lactate dehy drogenase
ln natural  logari thm
mg milligram
Mg++ magnesium
min minute
Revised Protocol No.: 02
Date: 02-Aug-2017 90
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
Term Definition
mL milliliter
mmHg millimeters of mercury
MR medical research
MS mass spectrometry
MTD maximum tolerated dose
g microgram
N number of subjects or observations
Na+ sodium
N/A not applicable
ng nanogram
NIMP non-invest igational medicinal products 
NSAID nonsteroidal ant i-inflammatory drug
PD pharmacodynamics
PK pharmacokinet ics
PO per os (by  [CONTACT_20511])
QC qualit y control
QD, qd quaque di e, once daily
R2coefficient of determinat ion
RBC red bl ood cell
SAE serious adverse event
SD standard deviat ion
SOP Standard Operating Procedures
Subj subject
t temperature
T time
TAO Trial Access Online, the BMS implementation of an EDC capabilit y
T-HALF Half life
TID, ti d ter in die, three times a day
Tmax, TMAX time of maximum observed concentration
UV ultraviolet
Revised Protocol No.: 02
Date: 02-Aug-2017 91
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
Term Definition
W washout
WBC white blood cell
WHO World Heal th Organizat ion
WOCBP wom en of childbearing potential
WNOCBP wom en notof childbearing potential
x g times gravit y
Revised Protocol No.: 02
Date: 02-Aug-2017 92
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
APPENDIX 2 STUDY GOVERANCE CONS IDERATIONS
The term  ‘Parti cipant’ i s used in the protocol to refer to a person who has consented to participate 
in the clinical research study.  The term ‘Subject’ used in the eCRF is intended to refer to a person 
(Parti cipant) who has consented to participate in the clinical research study .
REGULATORY AND ETHIC AL CONSIDERATIONS
GOOD CLINICAL PRACTI CE
This study  will be conducted in accordance wit h:
Good Clinical Pract ice (GCP), 
as defined by  [CONTACT_54015] (ICH)
in accordance with the ethical pr inciples underlying Euro pean Unio n Directive 2001/20/EC
[LOCATION_002] Code of Federal Regulations, Tit le 21, Part 50 (21CFR50) 
applicable local requirements.
The study  will be conducted in com pliance wi th the protocol . The protocol  and any amendme nts 
and the participant informed consent will receive approval/favorable opi[INVESTIGATOR_3078] n by [CONTACT_54016]/Independent Ethics Committee (IRB/IEC) , and regul atory  authori ties according to 
applicable local regulat ionsprior to init iation of the study .
All potenti al serious breaches must be reported to Sponsor or designee immediately. A serious 
breach is a breach of the conditions and principles of GCP in connect ion with the study  or the 
protocol , which is likely to affect, to a significant degree, the saf ety or physical or mental integrit y 
of the subjects of the study  or the sci entific value of the study.
Personnel involved in conducting this study  will be qualified by [CONTACT_54017], training, and 
experience to perform their respective tasks.
This study  will not use the services of study personnel where sancti ons have been invoked or where 
there has been scient ific misconduct or fraud ( e.g., loss of medical licensure, debarment). 
INSTITUTIONAL REVIEW BOARD/INDEPENDENT ET HICS COMMITTEE
Before study  initiation, the invest igator must have written and dated approval/favorable opi[INVESTIGATOR_3078] n 
from the IRB/IEC for the protocol, consent form , participant recruit ment materials (e.g., 
advert isements), and any other written informat ion to be provi ded to subjects. The invest igator or 
BMS shoul d also provide the IRB/IEC with a copy of the Investigator Brochure or product labeling 
inform ation to be provided to subjects and any  updates. 
The invest igator, Sponsor or designee should provide the IRB/IEC with re ports, updates and other 
inform ation (e.g., expedited safet y reports, amendments, and administrative letters) according to 
regul atory  requi rements or i nstitution procedures.
Revised Protocol No.: 02
Date: 02-Aug-[ADDRESS_229660] igator should not implement any deviati on or change to the protocol  without prior 
review and docum ented approval /favorabl e opi[INVESTIGATOR_53910]/IEC (and if 
applicable, also by [CONTACT_54018]) except where necessary to eliminate an immediate 
hazard(s) t o study subjects. 
If a deviat ion or change to a protocol is implemented to eliminate an immediate hazard(s) prior to 
obtaining relevant  approval/favorable opi[INVESTIGATOR_3078] n(s) the deviat ion or change will be submi tted, as 
soon as possible to:
IRB/IEC for 
Regulato ry Authori ty(ies), if applicable by  [CONTACT_54019] (per nat ional requirements)
Docum entati on of approval /favorabl e opi[INVESTIGATOR_3078] n signed by [CONTACT_54020](s)/IEC(s) and if applicable, also by [CONTACT_54021] h authorit y must be sent to BMS.
If an amendment substant ially alters the study  design or increases the potential risk to the 
participant : (1) the consent form must be revised and submi tted to th e IRB(s)/IEC(s) for review 
and approval/favorable opi[INVESTIGATOR_3078] n; (2) the revised form must be used to obtain consent from subjects 
currently enrolled in the study  if they are affected by [CONTACT_29991]; and (3) the new form must 
be used to obtain consent from new subjects prior to enrollment.
If the revisio n is done via an administrative letter, investig ators must inform  their IRB(s)/IEC(s).
FINANCIAL DISCLOSURE
Invest igators and sub-Invest igators will provi de the Sponsor with sufficient, accurate financia l 
inform ation in accordance with local regulati ons to allow the Sponsor to submit complete and 
accura te financial certification or disclosure statem ents to the appropriate healt h authori ties. 
Invest igators are responsible for provi ding information on financial interests during the course of 
the study  and f or [ADDRESS_229661] ensure that subjects are clearly and fully informed about the purpose, potential 
risks, and other crit ical issues regarding clinical studies in which they  volunteer to participate. 
In situat ions where consent cannot be g iven to subjects, their legally acceptable representatives (as 
per country guidelines) are clearly and fully informed about the purpose, potential risks, and other 
critical issues regarding clinical studies in which the participant volunteers to participat e. 
Sponsor or designee will provi de the investigator with an appropriate (i.e., Global or Local) sample 
inform ed consent form which will include all elem ents requi red by [CONTACT_12212], GCP and applicable 
regul atory  requirements. The sample inform ed consent form will adhere to the ethical principles 
that have their origin in the Declaration o f Helsinki.
Invest igators must:
Revised Protocol No.: 02
Date: 02-Aug-2017 94
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
Provi de a copy o f the consent form and written info rmation about the study in the language 
in which the participant is mo st proficient prior to clinical study  participat ion. The language 
must be non -technical  and easily understood. 
Allow time necessary for participant or participant 's legally acceptable representative to 
inquire about the details o f the study .
Obtain an informed consent signed and personally dated by [CONTACT_163901] 's legally acceptable representative and by [CONTACT_193223] n. 
Obtain the IRB/IEC’s wri tten approval /favorable opi[INVESTIGATOR_193192] y other informat ion to be provided to the subjects, prior to the beginning of the 
study , and after any  revisi ons are com pleted for new informat ion.
If inform ed consent is initially given by a partici pant’s legally acceptable representative or legal 
guardi an, and the participant subsequent ly beco mes capable of making and communicat ing his or 
her informed consent during the study, consent must additionally be obtained from the participant .
Revise the informed consent whenever important new informat ion beco mes available that is 
relevant to the participant 's consent. The invest igator, or a person designated by [CONTACT_3170], 
shoul d fully inform  the participant or the participant 's legally acceptable representative or legal 
guardi an, of all pertinent aspects of the study  and of any new information relevant to the 
participant 's willingness to conti nue participat ion in the study . This communication shoul d be 
docum ented. 
The confidentialit y of records that could ident ify subjects must be protected, respecting the privacy 
and confident iality rules applicable to regulatory  requi rements, the subjects' signed ICF and, in the 
US, the subjects’ signed HIPAA Authorizat ion.
The consent form must also include a statem ent that BMS and regul atory  authori ties have direct 
access to participant records. 
Subjects unable to give their written consent ( e.g., stroke or subjects with or severe dement ia) ma y 
only be enro lled in t he study with the consent of a legally acceptable representative. The partici pant
must also be informed about the nature of the study  to the extent compatible with his or her 
understanding, and shoul d this partici pant become capable, he or she shoul d personally  sign and 
date the consent form as soon as possible. The explicit wish of a participant who is unable to give 
his or her wri tten consent, but who is capable of forming an opi[INVESTIGATOR_193193], or to be withdrawn fro m, the clinical study at any time should be considered 
by [CONTACT_093].
The rights, safet y, and well -being of the study  subjects are the m ost important considerati ons and 
shoul d prevail  over interests of science and societ y.
SOURCE DOCUMENTS
The Investi gator is responsible for ensuring that the source data are accurate, legible , 
contemporaneous, ori ginal  and attributable, whether the data are hand -written on paper or entered 
Revised Protocol No.: 02
Date: 02-Aug-2017 95
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
electroni cally. If source data are created (first entered), modified, maintained, archived, retrieved, 
or transmitted electroni cally via computerized system s (and/or any other kind of electronic 
devices) as part of regulated clinical trial activities, such system s must be compliant with all 
applicable laws and regulati ons governing use of electronic records and/or electronic signatures. 
Such systems may inclu de, but are not limited to, electronic medical/healt h records (EMRs/EHRs), 
adverse event tracking/reporting, protocol  required assessments, and/or drug accountabilit y 
records).
When paper records from such systems are used in place of electronic format to perform regulated 
activit ies, such paper records should be certified copi[INVESTIGATOR_014]. A certified copy  consists of a copy of 
original  informat ion that has been verified, as indicated by a dated signature, as an exact copy 
having all o f the sam e attri butes and infor mation as the original. 
STUDY TREATMENT RECO RDS
Records for study treatments (whether supplied by [CONTACT_20444], its vendors, or the site) must substant iate 
study  treatment integrity and traceabilit y from  receipt, preparation, administration, and through 
destructio n or return. Records m ust be m ade available for revi ew at the request of BMS/desi gnee 
or a Health Authorit y.
Revised Protocol No.: 02
Date: 02-Aug-2017 96
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
If Then
Supplied by [CONTACT_20444] (or its vendors): Records or logs must comply with applicable 
regul ations and guidelines and should include:
amount received and placed in storage 
area
amount currently  in storage area
label ident ificat ion number or batch 
number
amount dispensed to and returned by  [CONTACT_37117] , including unique participant
ident ifiers
amount transferred to another area/site for 
dispensing or storage
nonstudy  disposi tion (e.g., l ost, wasted) 
amount destroy ed at study  site, if 
applicable
amount returned to BMS
retain samples for 
bioavailabilit y/bioequivalence, if 
applicable 
dates and init ials of person responsible for 
Invest igationalProduct 
dispensing/accountabilit y, as per the 
Delegati on of  Authori ty Form.
Sourced by [CONTACT_3725], and not supplied by [CONTACT_82769] (examples include IP sourced from 
the sites stock or commercial supply, or a 
specialt y pharmacy)The invest igator or desig nee accepts 
responsibilit y for document ing traceabilit y and 
study  drug integrity in accordance with 
requi rements applicable under law and the 
SOPs/standards of the sourcing pharmacy.   
These records should include:
label ident ificat ion number or batch 
number 
amount dispensed to and returned by  [CONTACT_37117] , including unique participant
ident ifiers
dates and init ials of person responsible for 
Invest igational Product 
dispensing/accountabilit y, as per the 
Delegati on of  Authori ty Form.
BMS or designee will provide forms to facilitate inventory control if the investigational site does not have an 
established system that meets these requirements.
Revised Protocol No.: 02
Date: 02-Aug-[ADDRESS_229662] safet y. CRFs may  be requested for AEs and/or laboratory  abnorm alities 
that are reported or iden tified during the course of the study .
For sites using the Sponsor or designee electronic data capture tool, electroni c CRFs will be 
prepared for all data collect ion fields except for fields specific to SAEs and pregnancy, which will 
be reported on the electroni c SAE form and Pregnancy  Surveillance form, respectively.  If 
electroni c SAE form is not available, a paper SAE form can be used. Spaces may be left blank 
only in those circumstances permitted by [CONTACT_3449] -specific CRF completion guidelines provi ded by 
[CONTACT_35886]. 
The confidentialit y of records that could ident ify subjects must be protected, respecting the privacy 
and confidentialit y rules in accordance wi th the applicable regulatory  requi rement(s).
The invest igator will maintain a signature [CONTACT_193231] m ake entri es and/or corrections on CRFs. 
The co mpleted CRF, SAE/pregnancy CRFs, must be pro mptly reviewed, signed, and dated by [CONTACT_54025] a subinvesti gator and who is delegated thi s task on the 
Delegati on of  Authori ty Form. Subinvest igators in Japan may not be delegated the CRF approval 
task For electronic CRFs, review and approval /signature [CONTACT_193232] c data capture tool. The investigator must retain a copy  of the CRFs including 
records of the changes and corrections.
Each individual electronically signing electroni c CRFs must meet Sponsor or designee training 
requi rements and must only access the BMS electroni c data capture tool using the unique user 
account provided by [CONTACT_35886]. User accounts are not to be shared or reassigned to other 
individuals
MONITORING
Sponsor or designee representatives will review data centrally to ident ify potenti al issues to 
determine a schedule of on -site visi ts for targeted review o f study  records. 
Representatives of BMS must be allowed to visit all study  site locati ons peri odically to assess the 
data qualit y and study  integrity. On si te they  will review study  records an d directly co mpare them 
with source docum ents, discuss the conduct of the study  with the invest igator, and verify that the 
facilit ies remain acceptable.
Revised Protocol No.: 02
Date: 02-Aug-[ADDRESS_229663] igator (or head of the study  site in Japan) must retain all study records and source 
docum ents for the maximum period requi red by [CONTACT_35888] , or 
institution procedures, or for the period specified by [CONTACT_54029], whichever is longer. The 
investigator (or head of the study site in Japan) must contact [CONTACT_186767] .
BMS or desi gnee will notify the invest igator (or head of the study  site in Japan) when the study 
records are no longer needed.
If the investigator withdraws from the study  (e.g., relocation, retirement), the records shall be 
transferred to a mutually agreed upon designee ( e.g., anoth er investigator, study site, IRB). Notice 
of such transfer will be given in writ ing to BMS or designee. 
RETURN OF STUDY TREA TMENT
For thi s study , study  treatm ents (those supplied by  [CONTACT_20444], a vendor or sourced by  [CONTACT_3170]) 
such as partially  used stud y treatm ent containers, vials and syringes may  be destroy ed on si te. 
If.. Then
Study  treatments supplied by [CONTACT_20444] (including 
its vendorsAny unused study  treatm ents supplied by [CONTACT_193224] y, or to meet local regulations (e.g., 
cytotoxi cs or bi ologics).
If study  treatments will be returned, the return 
will be arranged by [CONTACT_193225].
Study  treatm ents sourced by [CONTACT_66574], not supplied 
by [CONTACT_20444] (or its vendors) (examples include 
study  treatments sourced from the sites stock 
or commercial supply, or a specialt y 
pharmacy)It is the invest igator’s or designee’s 
responsibilit y to dispose of all containers 
according to the institutional guidelines and 
procedures.
Revised Protocol No.: 02
Date: 02-Aug-[ADDRESS_229664] igator’s or designee’s responsibilit y to arrange for disposal, provided that procedures 
for proper disposal have been established according to applic able federal, state, local, and 
institutional guidelines and procedures, and provided that appropriate records of disposal are kept. 
The fo llowing minimal standards must be met:
On-site disposal  pract ices must not expose humans to risks fro m the drug.
On-site disposal  practices and procedures are in agreement with applicable laws and 
regul ations, including any special requirements for controlled or hazardous substances.
Written procedures for on-site disposal  are available and followed. The procedures must 
be filed wit h the site’s SOPs and a copy  provi ded to BMS upon request.
Records are maintained that allow for traceability of each container, including the date 
disposed of, quant ity disposed, and ident ificat ion of the person disposing the containers. 
The method of disposal, i.e., incinerator, licensed sanitary landfill, or licensed waste 
disposal  vendor m ust be docum ented.
Accountabilit y and disposal records are complete, up-to-date, and available for the Moni tor 
to revi ew throughout the clinical trial peri od.
It is the invest igator’s or designee’s responsibilit y to arrange for di sposal  of all empt y containers.
If condit ions for destruction cannot be met the responsible Study Monitor will make arrangements 
for return of study treatments provided by [CONTACT_20444] (or its vendors). Destruction of non-study 
treatm ents sourced by [CONTACT_779], not supplied by [CONTACT_20444], is solely the responsibilit y of the invest igator 
or desi gnee.
For this study , study  treatm ents (those supplied by [CONTACT_54024] )such as full or partially 
used study  treatm ent containers, vials, sy ringes cannot be destroy ed on -site.
It is however, the invest igator’s or designee’s responsibilit y to arrange for disposal of all empt y 
study  treatment containers, provided that procedures for proper disposal have been established 
according to applicable federal, state, local, and institutional guidelines and procedures, and 
provi ded that appropriate records of disposal are kept. The return of full or partially used study 
treatm ents supplied by  [CONTACT_35889] i ts vendors will be arranged by [CONTACT_186769].
CLINICAL STUDY REPOR T AND PUBLICATIONS
A Signatory  Invest igator must be selected to sign the clinical study report. 
For this protocol, the Signatory Invest igator will be selected as appropriate based on the following 
criteria:
External Principal Invest igator designated at protocol development
National Coordinating Invest igator 
Study  Steering Committee chair or their designee
Parti cipant recruitment ( e.g., among the top quartile of enrollers)
Involvement in t rial design
Revised Protocol No.: 02
Date: 02-Aug-2017 100
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
Regional representati on (e.g., among top quartile of enrollers from a specified region or 
country )
Other criteria (as determined by  [CONTACT_2362] )
For this single site protocol, the Principal Invest igator for the site will sign the clinical s tudy report.
The data collected during thi s study  are confident ial and propri etary  to Sponsor or desi gnee. Any 
publicat ions or abstracts arising from this study  must adhere to the publicat ion requi rements set 
forth in the clinical trial agreement (CTA) governing [Study  site or Investi gator] participation in 
the study . These requi rements include, but are not limited to, submitting proposed publicat ions to 
Sponsor or designee at the earliest practicable time prior to submissio n or presentation and 
otherwi se within the time period set forth in the CTA.
Revised Protocol No.: 02
Date: 02-Aug-2017 101
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
APPENDIX 3 ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS : 
DEFINITIONS AND PROC EDURES FOR RECORDING , 
EVALUATING, FOLLOW U P AND REPORTING
ADVERSE EVENTS
Adverse Event Definition:
An Adverse Event (AE) i s defined as any  new untoward m edical occurrence or worsening of a 
preexist ing medical condit ion in a clinical invest igation participant administered study drug and 
that does not necessarily have a causal relat ionship wi th this treat ment. 
An AE can therefore be any unfavorabl e and unintended sign (such as an abnorm al laboratory 
finding), symptom, or disease tem porally  associ ated wi th the use of  study  drug, whether or not 
considered related to the study  drug.
Revised Protocol No.: 02
Date: 02-Aug-2017 102
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
SERIOUS ADVERSE EVEN TS
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any 
dose:
Results in death
Is life-threatening (defined as an event in which the participant was at ri sk of  death at the time 
of the event; it does not refer to an event which hypotheti cally might have caused death if it 
were m ore severe)
Requi res inpat ient hospi[INVESTIGATOR_193194] (see NOTE 
below)
NOTE: 
The fo llowing hospi [INVESTIGATOR_193195]: 
oa visit to the emergency room or other hospi[INVESTIGATOR_20347] < 24 hours, that does 
not result in admissi on (unless considered an important medical or life-
threatening event)
oelective surgery, planned prior to signing consent
oadmissio ns as per protocol f or a pl anned medical/surgical procedure
orouti ne health assessment requiring admissio n for baseline/trending of health 
status ( e.g., routine colonoscopy )
omedical/surgical admissi on other than to rem edy ill health and planned prior to 
entry  into the study . Appropri ate documentati on is requi red in these cases
oadmissio n encountered for another life circumstance that carries no bearing on 
healt h status and requires no medical/surgical intervent ion (e.g., lack o f housing, 
economic inadequacy , caregiver respi [INVESTIGATOR_040], family circumstances, administrative 
reason)
oadmissio n for administration of anticancer therapy in the absence of any other 
SAEs (applies to oncology  protocol s)
Results in persistent or significant disabilit y/incapacit y
Is a congenital ano maly/birth defe ct
is an important m edical  event (defined as a medical event(s) that m ay not be immediately life-
threatening or resul t in death or hospi [INVESTIGATOR_3092], based upon appropri ate medical and 
scientific judgment, may jeopardi ze the participant or may requi re intervent ion [e.g., medical, 
surgi cal] to prevent one of the other serious outcomes listed in the definit ion above.) Examples 
of such events include, but are not limited to, intensive treatment in an emergency  room or at 
home for allergic bronchospasm; blood dyscrasias or convulsio ns that do not resul t in 
hospi [INVESTIGATOR_28689].) Potenti al drug induced liver injury  (DILI) is also considered an important 
medical event. (See Section 8.1.1 for the definit ion of potenti al DILI.) 
Revised Protocol No.: 02
Date: 02-Aug-2017 103
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
Suspected transmissio n of an infectious agent (e.g., pathogenic or nonpathogenic) via the study 
treatm entis an SAE. 
Although pregnancy , overdose, cancer, and potent ial drug induced liver injury (DILI) are not 
always serious by [CONTACT_186770], these events m ust be handled as SAEs. (See Section 9.2.5
for reporting pregnancies).
Any co mponent of a study  endpoint that i s considered related to study  therapy  shoul d be reported 
as SAE (e.g., death is an endpo int, if death occurred due to anaphylaxis, anaphylaxis must be 
reported).
EVALUATING AES AND S AES
Assessment of Causality
The causal relationship to study  drug is determined by a physician and shoul d be used to 
assess all adverse events (AE). The causal relat ionship can be one of the fo llowing:
Related: There is a reasonable causal relati onship between study  drug 
administration and the AE.
Not related: There is not a reasonable causal relationship between study  drug 
administration and the AE. 
The term "reasonable causal  relationship" means there is evidence to suggest a causal 
relationship. 
Follow -up of AEs and SAEs
If only limited information is initially available, follow-up reports are required. (Note: 
Follow-up SAE reports must include the same investigator term(s) init ially reported.) 
If an ongoing SAE changes in its intensity or relationship to study  drug or if new 
inform ation beco mes available, the SAE report must be updated and submitted within 24 
hours to BMS (or designee) using th e same procedure used for transmitting the init ial SAE 
report.
All SAEs must be fo llowed to resol ution or stabilization.
Revised Protocol No.: 02
Date: 02-Aug-2017 104
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
REPORTING OF SAES TO SPONSOR OR DESIGNEE
SAEs, whether related or not related to study drug, and pregnancies must be 
reported to BMS (or designee) within 24 hours of awareness o f the event.
SAEs must be recorded on the SAE Report Form; pregnancies on a Pregnancy 
Surveillance Fo rm (electroni c or p aper forms).
The preferred method for SAE data reporting collection is through the eCRF.
The paper SAE/pregnancy surveillance forms are only intended as a back -up option 
when the eCRF system is not funct ioning.
oIn this case, the paper forms are to be trans mitted via email or confirmed 
facsimile (fax) transmissio n to:
SAE Email Address: Refer to Contact [CONTACT_20491].
SAE Facsimile Number: Refer to Contact [CONTACT_20491].
For studi es capturing SAEs through electronic data capture (EDC), el ectronic submissio n 
is the requi red method for reporting. In the event the electroni c system  is unavailable for 
transmissio n, paper forms must be used and submit ted immediately. When paper forms are 
used, the original paper forms are to remain on site.
SAE Telephon e Contact (required for SAE and pregnancy reporti ng): Refer to Contact 
[CONTACT_186771].: 02
Date: 02-Aug-2017 105
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
APPENDIX 4 WOMEN OF CHILDBEARIN G POTENTIAL DEFINITI ONS AND 
METHODS OF CONTRACEP TION
DEFINITIONS
Woman of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming post-menopausal unless 
perm anent ly sterile. Perm anent sterilizat ion methods include hysterectomy, bilateral 
salpi[INVESTIGATOR_1656] , and bilateral  oophorectomy.
Women in the following categories are not considered WOCBP
Prem enarchal
Prem enopausal  female wi th 1 of the fo llowing:
Docum ented hysterectomy
Docum ented bilateral  salpi[INVESTIGATOR_1656]
Docum ented bilateral  oophorectomy
Note: Docum entati on can come from the site personnel’s review of the partici pant’s medica l 
records, medical examinat ion, or m edical history  interview.
Postmenopausal  female
A postm enopausal  state is defined as [ADDRESS_229665] a serum  follicle stimulat ing horm one, (FSH) level > 40 
mIU/mL to confirm menopause.
CONTRACEPTION GUIDAN CE FOR FEMALE PARTIC IPANTS OF CHILD BEAR ING 
POTENTIAL
One of the highly effect ive methods of contraception listed below is required during study duration 
and until the end of relevant systemic exposure, defined as 5 monthsafter the end of study 
treatm ent. 
Local  laws and regulat ions may require use of altern ative and/or addit ional contraception methods.
Revised Protocol No.: 02
Date: 02-Aug-2017 106
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
Highly Effective Contraceptive Methods That Are User Dependent 
Failure rate of <1% per year w hen used consistently and correctly.a
Combined (estrogen -and progestogen -containing) horm onal contracepti on associated with 
inhibit ion of ovulationb 
oral 
intravaginal 
transderm al 
Progestogen -only hormonal contraception associated with inhibition of ovulationb 
oral 
injectable 
Highly Effective Methods That Are User Independent
Implantable progestogen -only horm onal contracepti on associated with inhibit ion of 
ovulationb
Horm onal methods of contracepti on including oral contraceptive pi[INVESTIGATOR_20303] a 
combinat ion of estrogen and progesterone ,vaginal ring, injectables, implants and 
intrauterine horm one-releasing system  (IUS)c
Intrauterine device (IUD)c
Bilateral tubal occlusio n
Vasectomized partner 
A vasectomized partner is a highly effective contraception method provided that the partner 
is the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. 
If not, an additional highly effective method of contraception should be u sed. 
Sexual abstinence
Sexual abstinence is considered a highly effective method only if defined as refraining from 
heterosexual intercourse during the entire period of risk associated with the study drug. The 
reliability of sexual abstinence needs to b e evaluated in relation to the duration of the study 
and the preferred and usual lifestyle of the participant.
It is not necessary to use any other method of contraception when complete abstinence is 
elected. 
WOCBP participants who choose complete abstine nce must continue to have pregnancy 
tests, as specified in Section 2. 
Acceptable alternate methods of highly effective contraception must be discussed in the 
event that the WOCBP participants chooses to forego complete abst inence 
Revised Protocol No.: 02
Date: 02-Aug-2017 107
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
NOTES: 
aTypi[INVESTIGATOR_186722] . Use should be consistent 
with local regulations regarding the use of contraceptive methods for participants participating in clinical studies. 
bHormonal contraception may be susceptible to interactio n with the study drug, which may reduce the efficacy 
of the contraceptive method.  Hormonal contraception is permissible only when there is sufficient evidence that 
the IMP and other study medications will not alter hormonal exposures such that contraception would be 
ineffective or result in increased exposures that could be potentially hazardous.  In this case, alternative methods 
of contraception should be utilized. 
cIntrauterine devices and intrauterine hormone releasing systems are acceptable methods of contraception in the 
absence of definitive drug interaction studies when hormone exposures from intrauterine devices do not alter 
contraception effectiveness
Unacceptable Methods of Contraception
Male or female condom with or wi thout spermicide.  Male and female condo ms cannot be 
used simultaneously
Diaphragm  with spermicide
Cervical cap wit h spermicide
Vaginal Sponge with spermicide
Progestogen -only oral hormonal contracepti on, where inhibit ion of ovulat ion is not the 
primary  mechanism o f action
Periodic abst inence (calendar, symptot hermal, post -ovulation methods)
Withdrawal (coitus interruptus).
Spermicide only
Lactati on amenorrhea m ethod (LAM)
CONTRACEPTION GUIDAN CE FOR MALE PARTICIP ANTS WITH PARTNER(S) OF 
CHILD BEA RING POTENTIAL.
Male participants with female partners of childbearing potenti al are eligible to participate if they 
agree to the fo llowing during the treatment and until the end of relevant sy stemic exposure.
Inform  any and all partner(s) of their participation in a clinical drug study  and the need to 
comply with contracepti on instructi ons as di rected by  [CONTACT_17062].
Male participants are requi red to use a condom for study  duration and until end of relevant 
systemic exposure defined as 7 months after the end of study  treatm ent.
Female partners of males participat ing in the study  to consider use of effective methods of 
contraception unt il the end o f relevant systemic exposure, defined as 7 months after the end o f 
treatm ent in the m ale participant.
Male participants with a pregnant or breastfeeding partner must agree to remain abst inent fro m 
penile vaginal intercourse or use a male condo m during each epi[INVESTIGATOR_53915] 7 m onths after the end of study  treatm ent. 
Refrain from donating sperm  for th e duration of the study  treatment and until 7 months after 
the end of study  treatm ent.
Revised Protocol No.: 02
Date: 02-Aug-[ADDRESS_229666] ion 9.2.5 and the Appendix for Adverse Events and Serious 
Adverse Events Definit ions and procedures for Evaluat ing, Fo llow-up and Reporti ng.
Revised Protocol No.: 02
Date: 02-Aug-[ADDRESS_229667] 1.1 GUIDELINE S
1 EVALUATION OF LESION S
At baseline, tumor lesions/lymph nodes will be categori zed measurable or non-measurable as 
follows:
1.1 Measurable
Tumor lesio ns: Must be accurately measured in at least one dimension (longest diameter in the 
plane of measurement is to be recorded) with a minimum size of:
1.[ADDRESS_229668] scan (CT scan slice thickness no greater than 5 mm)
2. 10 mm caliper measurement by [CONTACT_461]  (lesio ns which cannot be accurately measured 
with calipers shoul d be recorded as non -measurable)
3.[ADDRESS_229669] x -ray
Malignant lymph nodes: To be considered patho logically  enlarged and measurable, a lymph node 
must be [ADDRESS_229670] scan (CT scan slice thickness recommended 
to be no greater than 5 mm).
Lymph nodes merit special ment ion since they are norm al anatomic al structures which may be 
visible by [CONTACT_33490]. Pathol ogical  nodes which are defined as 
measurable and may be ident ified as target lesions must meet the criterion of a  short axis of 
15mm by [CONTACT_3610]. Only the short axi s of these nodes will contribute to the baseline sum. The 
short axis of the node i s the di ameter normally  used by  [CONTACT_102470] j udge if a node is involved 
by [CONTACT_193226]. Nodal size is normally reported as two dimensio ns in the plane in which the image 
is obtained (for CT scan this is almo st always the axial plane; for MRI the plane of acquisition 
may be axial , saggital or coronal ). The smaller of these measures is the short axis. For example, 
an abdo minal node which is reported as being 20 mm x 30 mm has a short axis of 20mm and 
qualifies as a malignant, measurable node. In this example, 20 mm should be recorded as the node 
measurement. All other pathol ogical nodes (those wi th short axi s 10 mm but < 15 mm) should 
be considered non-target lesions. Nodes that have a short axis < 10 mm are considered 
non-patho logical and should not be recorded or fo llowed.
1.2 Non-Measurable
All other lesions are considered non-measurable, including small lesio ns (longest diameter 
< 10 mm or pathological lymph nodes with 10 to < 15 mm short axis) as well as truly 
non-measurable lesions. Lesio ns considered truly non-measurable include: leptomeningeal 
disease, ascites, pleural or pericardial effusi on, inflammatory breast disease, lymphangit ic 
involvement of skin or lung, abdo minal masses/abdo minal organom egaly  identified by [CONTACT_193227].
Revised Protocol No.: 02
Date: 02-Aug-2017 110
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
2 BASELINE DOCUMENTATI ON OF ‘TARGET’ AND ‘ NON- TARGET’ 
LESIONS
When more than one measurable lesio n is present at baseline all lesions up to a m aximum o f five 
lesions total (and a maximum of two lesions per organ) representative of all invo lved organs should 
be ident ified as target lesions and will be recorded and measured at baseline (this means in 
instances where patients have only one or two organ sites involved a maximum of two and four 
lesions respect ively will be recorded).
Target l esions shoul d be selected on the basis of their size (l esions wi th the longest di ameter), be 
representative of all involved organs, but in additi on shoul d be thosethat lend themselves to 
reproducible repeated m easurem ents. It m ay be the case that, on occasi on, the largest lesio n does 
not lend itself to reproducible measurement in which circumstance the next largest lesion which 
can be measured reproducibly should b e selected.
A sum of the diameters (longest for non-nodal  lesions, short axis for nodal  lesions) for all target 
lesions will be calculated and reported as the baseline sum diameters. If lymph nodes are to be 
included in the sum, then as noted above, only t he short axi s is added into the sum . The baseline 
sum diameters will be used as ref erence to f urther characteri ze any objective tum or regressi on in 
the measurable dimensio n of the disease.
All other lesions (or sites of disease) including patho logical lymph nodes shoul d be identified as 
non-target lesions and shoul d also be recorded at baseline. Measurements are not required and 
these lesions shoul d be followed as ‘present’, ‘absent’, or in rare cases ‘unequivocal progression’ 
(more details to follow). In addition, it is possible to record multip le nontarget lesio ns involving 
the same organ as a single item on the case record form (eg, ‘multiple enlarged pelvic lymph nodes’ 
or ‘m ultiple liver m etastases’).
[ADDRESS_229671] ete Response (CR): Disappearance of all target lesions. Any patho logical lymph nodes 
(whether target or non -target) m ust have reduct ion in short axi s to < 10 mm.
Partial Response (PR): At least a 30% decrease in the sum of diameters of target l esions, taki ng 
as reference the baseline sum diameters.
Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking 
as reference the smallest sum on study  (this includes the baseline sum if that is the 
smallest on study ). In addition to the relative increase of 20%, the sum must also 
demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or 
more new l esions is also considered progression).
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to 
qualify  for PD, taking as reference the smallest sum diameters while on study .
Revised Protocol No.: 02
Date: 02-Aug-2017 111
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
3.1.1 Special Notes on the Assessment of Target Lesions
[IP_ADDRESS] Lymph nodes
Lymph nodes ident ified as target lesions shoul d always have the actual short axis measurement 
recorded (m easured in the same anatomical plane as the baseli ne examinat ion), even if the nodes 
regress to below 10 mm o n study. This means that when lymph nodes are included as target lesions, 
the ‘sum’ of lesions may not be zero even if compl ete response criteria are met, since a norm al 
lymph node is defined as ha ving a short axis of < [ADDRESS_229672] achieve a short axis < 10 mm . For PR, S D and 
PD, the actual short axis measurement of the nodes is to be included in the sum of target lesio ns.
[IP_ADDRESS] Target lesions that become ‘too small to measure’
While on study , all lesions (nodal  and non-nodal ) recorded at baseline shoul d have their actual 
measu rements recorded at each subsequent evaluat ion, even when very small (eg,2 mm). 
However, sometimes lesions or lymph nodes which are recorded as target lesions at baseline 
beco me so faint on CT scan that the radiologist may not feel comfortable assigning an exact 
measure and may report them as being ‘too small to measure’. When this occurs it is important 
that a value be recorded on the case report form. If it is the opi[INVESTIGATOR_1649] o f the radio logist that the lesio n 
has likely disappeared, the measurement should be recorded as 0 mm . If the lesi on is believed to 
be present and is faint ly seen but too small to measure, a default value of 5 mm should be assigned 
(Note: It is less likely that this rule will be used for lymph nodes since they usually have a definable 
size when normal and are frequently surrounded by [CONTACT_193228]; however, 
if a lymph node is believed to be present and is faintly seen but too small to measure, a defaul t 
value of 5 mm should be assigned in this circumstance as well). T his default value is derived fro m 
the [ADDRESS_229673] slice thickness (but should not be changed with varying CT slice thickness). The 
measurement of these lesions is potenti ally non-reproducible, therefore providing this defaul t 
value will prevent false responses or progressions based upon measurement error. To reiterate, 
however, if the radio logist is able to provide an actual measure, that should be recorded, even if it  
is below 5 mm.
[IP_ADDRESS] Lesions that split or coalesce on treatment
When non-nodal  lesions ‘fragment’, the longest diameters of the fragmented portions shoul d be 
added together to calculate the target lesion sum. Similarly, as lesions coalesce, a plane between 
them may be maintained that would aid in obtaining maximal diameter measurements of each 
individu al lesion. If the lesions have truly coalesced such that they are no longer separable, the 
vector of the longest diameter in this instance shoul d be the maximal longest diameter for the 
‘coal esced lesio n’.
3.2 Evaluation of Non -Target Lesions
This section provides the defini tions of the criteria used to de termine the tumor response for the 
group of non -target lesio ns. While some non -target lesio ns may actually be measurable, they need 
Revised Protocol No.: 02
Date: 02-Aug-2017 112
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
not be measured and instead shoul d be assessed only qualitatively at the time points specified in 
the protocol.
Complete Response (CR): Disappearance of all non-target lesions and normalizat ion of tumor 
marker level. All lymph nodes must be no n-pathol ogical in size (< 10mm short axis). 
Non-CR/Non -PD: Persi stence of one or more non-target lesion(s) and/or maintenance of tumor 
marker l evel above the norm al limits.
Progressive Disease (PD): Unequivocal progression (see comments below) of exist ing non -target 
lesions. (Note: the appearance of one or more new lesio ns is also considered 
progression).
3.2.1 Special Notes on Assessment of Progression of Non -Target Disease
The concept of progression of non -target di sease requi res addi tional explanati on as fo llows:
[IP_ADDRESS] When the patient also has measurable disease
In this setting, to achieve ‘unequivocal progressi on’ on the basis of the non-target disease, there 
must be an overall level o f substant ial worsening in non -target di sease such that, even in presence 
of SD or PR in target disease, the overall tumor burden has increased sufficient ly to merit 
discontinuat ion of therapy (see examples in Appendix 2 and further details below). A modest 
‘increase’ in the size of one or more non-target lesio ns is usually not sufficient to qualify for 
unequivocal progressi on status. The designat ion of overall progressi onsolely on the basis of 
change in non-target disease in the face of  SD or PR of  target di sease will  theref ore be extrem ely 
rare.
[IP_ADDRESS] When the patient has only non -measurable disease
This circumstance arises in so me trials when it is not a criterion of study en try to have measurable 
disease. The same general  concepts apply here as noted above, however, in this instance there is 
no measurable disease assessment to factor into the interpretati on of an increase in non -measurable 
disease burden. Because worsening in non-target disease cannot be easily quant ified (by [CONTACT_154020]: 
if all lesio ns are truly non -measurable) a useful test that can be applied when assessing patients for 
unequivocal progressi on is to consider if the increase in overall  disease burden based onthe change 
in non-measurable disease is comparable in magnitude to the increase that would be requi red to 
declare PD for measurable disease: ie, an increase in tumor burden represent ing an addit ional 73% 
increase in ‘volume’ (which is equivalent to a 20% increase diameter in a measurable lesion). 
Examples include an increase in a pleural  effusion from ‘trace’ to ‘large’, an increase in 
lymphangit ic disease fro m localized to widespread, or may be described in protocols as ‘suffic ient 
to require a change in therapy’. If ‘unequivocal progression’ is seen, the patient shoul d be 
considered to have had overall PD at that point. While it would be ideal to have objective cri teria 
to apply to non-measurable disease, the very nature of that disease makes it impossibl e to do so; 
therefore the increase must be substant ial.
Revised Protocol No.: 02
Date: 02-Aug-2017 113
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
3.2.2 New Lesions
The appearance of new malignant lesio ns denotes disease progression; therefore, some comments 
on detection of new lesions are important. There are no specific criteria for the identificat ion of 
new radiographic lesions; however, the finding of a new lesion should be unequivocal: ie, not 
attributable to differences in scanning technique, change in imaging modality or findings thought 
to represent something other than tumor (for example, some ‘new’ bone lesio ns may be simply 
healing or flare of pre -exist ing lesio ns). This is parti cularly important when the pat ient’s baseline 
lesions show partial or complete response. For example, necrosis of a liver lesio n may be reported 
on a CT s can report as a ‘new’ cyst ic lesio n, which it is not.
A lesio n ident ified on a follow -up study  in an anatomical location that was not scanned at baseline 
is considered a new lesio n and will indicate disease progression. An example of this is the pat ient 
who has visceral disease at baseline and while on study has a CT or MRI brain ordered which 
reveals metastases. The patient’s brain metastases are considered to be evidence of PD even if 
he/she did not have brain imaging at baseline.
If a new lesio n is equiv ocal, for example because of its small size, continued therapy and fo llow-up 
evaluat ion will  clarify if i t represents truly new disease. If repeat scans confirm there is definit ely 
a new lesion, then progression shoul d be declared using the date of  the initial scan. While FDG -
PET response assessments need addit ional study, it is somet imes reasonable to incorporate the use 
of FDG-PET scanning to complement CT scanning in assessment of progressi on (parti cularly 
possible ‘new’ disease). New lesions on the basis of FDG -PET imaging can be ident ified according 
to the following algorithm:
1.Negative FDG -PET at baseline, with a positive FDG -PET at follow-up is a sign of PD based 
on a new lesio n.
2.No FDG -PET at baseline and a positive FDG -PET at follow-up: If the positive FDG -PET at 
follow-up corresponds to a new site of disease confi rmed by [CONTACT_4654], this is PD. If the positive 
FDG -PET at f ollow-up is not confi rmed as a new site of disease on CT, addi tional follow-up 
CT scans are needed to determine if there is truly progress ion occurring at that si te (if so, the 
date of  PD will be the date of  the initial abnorm al FDG-PET scan). If the positive FDG -PET 
at follow-up corresponds to a pre -exist ing site of disease on CT that i s not progressing on the 
basis of the anatomic images, this is not PD.
3.[ADDRESS_229674] response recorded from  the start of the study  treatm ent until 
the end of treatment taking into accoun t any requi rement for confirmation. The patient’s best 
overall response assignment will depend on the findings o f both target and non -target disease and 
will also take into consideration the appearance of new lesions. Furtherm ore, depending on the 
nature of the study  and the protocol  requi rements, i t may also requi re confi rmatory  measurement.
Revised Protocol No.: 02
Date: 02-Aug-[ADDRESS_229675] non-measurable (therefore non-target) 
disease only , Table 3.3.2 -2is to be used. 
Table 3.3.2 -1: Time Point Response: Patients With Target (+/ -Non-Target) 
Disease
Target Lesions Non-Target Lesions New Lesions Overall Response
CR CR No CR
CR Non-CR/no n-PD No PR
CR Not evaluated No PR
PRNon-PD or not all 
evaluatedNo PR
SDNon-PD or not all 
evaluatedNo SD
Not all evaluated Non-PD No NE
PD Any Yes or No PD
Any PD Yes or No PD
Any Any Yes PD
CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease and NE = inevaluable
Table 3.3.2 -2: Time Point Response: Patients with Non -target Disease Only
Non-Target Lesions New Lesions Overall Response
CR No CR
Non-CR/no n-PD No Non-CR/no n-PDa
Not all evaluated No NE
Unequivocal PD Yes or No PD
Any Yes PD
CR = complete response, PD = progressive disease and NE = inevaluable
aNon-CR/no n-PD is preferred over SD for non-target disease since SD is increasingly used as endpoint for 
assessment of efficacy in some trials so to assign this category when no lesions can be measured is not advised.
3.3.[ADDRESS_229676] response determination of complete or partial response requi res confirmation: Complete or 
partial responses may be claimed only if the criteria for each are met at a subsequent time point of 
Revised Protocol No.: 02
Date: 02-Aug-2017 115
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
[ADDRESS_229677] overall  response can be interpreted as in Table 3.3.3 -
1.
Special note on response as sessment: When nodal disease is included in the sum o f target lesio ns 
and the nodes decrease to ‘norm al’ size (< 10 mm), they  may still have a measurement reported 
on scans. This measurement should be recorded even though the nodes are normal in order not to 
overstate progression shoul d it be based on increase in size of the nodes. As noted earlier, this 
means that patients with CR may not have a total sum of ‘zero’ on the case report form (CRF).
Table 3.3.3 -1: Best Overall Response (Confirmation of CR&PR R equired)
Overall Response 
First Time PointOverall Response 
Subsequent Time PointBEST Overall Response
CR CR CR
CR PR SD, PD OR PRa
CR SDSD provided minimum criteria for SD durationbmet, 
otherwise, PD
CR PDSD provided minimum criteria for SD durationbmet, 
otherwise, PD
CR NESD provided minimum criteria for SD durationbmet, 
otherwise, NE
PR CR PR
PR PR PR
PR SD SD
PR PDSD provided minimum criteria for SD durationbmet, 
otherwise, PD
PR NESD provided minimum criteria for SD durationbmet, 
otherwise, NE
NE NE NE
CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease, and 
NE=inevaluable
aIf a CR is truly  met at first time point, then any  disease seen at a subsequent time point, even disease meeting PR 
criteria relative to baseline, makes the disease PD at that point (since dise ase must have reappeared after CR). Best 
response would depend on w hether minimum duration for SD was met. However, sometimes ‘CR’ may be claimed 
when subsequent scans suggest small lesions were likely still present and in fact the patient had PR, not CR a t the 
first time point. Under these circumstances, the original CR should be changed to PR and the best response is PR.
bMinimum criteria for SD duration is 6 weeks.
3.3.4 Confirmation Scans
Verifica tion of Response: To b e assigned a status of CR or PR, changes in tumor m easurements 
must be confirmed by [CONTACT_193229].: 02
Date: 02-Aug-[ADDRESS_229678] met. For this study , the next scheduled tumor 
assessment can meet this requirement.
Verificat ion of Progressi on:Progression of di sease shoul d be verified in cases where progression 
is equivocal. If repeat scans confirm PD, then progressio n should be declared using the date of the 
initial scan. If repeat scans do not confirm PD, then the subject is considered to not have 
progressive disease.
Revised Protocol No.: 02
Date: 02-Aug-[ADDRESS_229679] ATIC RCC DATABASE 
CONSORTIUM (IMDC) PR OGNOSTIC CRITERIA
Adverse Prognostic Factors
Clinical 
KPS < 80%
Time from diagnosis to treatment < 1 year
Laboratory 
Hemoglobin < LLN
Corrected calcium > ULN
Absolute neutrophil count > ULN
Platelet count > ULN
LLN = Lower limit of normal
ULN = Upper limit of normal
Corrected calcium (mg/dL) = measured total Ca (mg/dL) + 0.8 (4.0 -serum albumin [g/dL]), where 
4.0 represents the average albumin level in g/dL.
Corrected calcium (mm ol/L) = measured total Ca (mmo l/L) + 0.02 (40 -serum albumin [g/L]), 
where 40 represents the average albumin level in g/L
Risk Group Based on Nu mber of Adverse Prognostic Factors
Number of Adverse Prognostic Factors Present Risk Group
0 Favorable
1-2 Intermediate
3-6 Poor
Reference:  Heng D, Xie W, Regan M, et al. Prognostic factors for overall survival in patients with metastatic renal 
cell carcinoma treated with vascular endothelial growth factor -targeted agents: results from a large, multicenter study. 
J Clin Oncol 2009; 27(34):5794 -5799 .
Revised Protocol No.: 02
Date: 02-Aug-[ADDRESS_229680] of his needs60 2
Symptomatic, but in 
bed < 50% of the dayRequires considerable assistance and 
frequent medical care50 2
Disabled. Requires special care and 
assistance40 3
Needs to be in bed 
>50% of the day, but 
not bedridden Severely  disabled. Hospi[INVESTIGATOR_193196]30 3
Very  sick. Hospi[INVESTIGATOR_5186] n necessary . 
Active supportive treatment necessary20 4
Unable to get out of 
bed
Moribund 10 4
Dead 0 5 Dead
Revised Protocol No.: 02
Date: 02-Aug-[ADDRESS_229681] , especially prior to an invasive diagnostic or 
therapeuti c procedure, is recommended. 
The frequency and severit y of the rel ated adverse events covered by  [CONTACT_193230] -oncol ogy agent or regimen being used.
Revised Protocol No.: 02
Date: 02-Aug-2017 120
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
Revised Protocol No.: 02
Date: 02-Aug-2017 121
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
Revised Protocol No.: 02
Date: 02-Aug-2017 122
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
Revised Protocol No.: 02
Date: 02-Aug-2017 123
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
Revised Protocol No.: 02
Date: 02-Aug-2017 124
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
Revised Protocol No.: 02
Date: 02-Aug-2017 125
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
Revised Protocol No.: 02
Date: 02-Aug-2017 126
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
Revised Protocol No.: 02
Date: 02-Aug-2017 127
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
Myotoxicity  (Myositis, M yocarditis, Rhabdomy olysis) 
Adverse Event Management A lgorithm 
Rule out non -inflammatory causes.  If non -inflammatory, cause, treat accordingly and continue I -O therapy.
Grade of Myotoxicity*             Management              Follow UP
Grade 1:
Asymptomatic with laboratory or 
cardiac imaging abnormalities 
(myocarditis)
Mild pain (myositis)•Consider delay of I -O therapy
•Monitor CPK and troponin and emergence of new 
symptoms; EKG
•Cardiology consultation for abnormal cardiac 
labs/imaging
•Consider steroids (up to 2 mg/kg/day 
methylprednisolone IV or oral equivalent)
•Symptomatic therapy (myositis)•Close monitoring for new or 
worsening symptoms
•If worsens : Treat as Grade 2 
or 3/4
Grade 2 :
Symptoms with mild to moderate 
activity  or exertion (my ocarditis)
Moderate pain associated with 
weakness; pain limiting 
instrumental activities of daily 
living (myositis)•Delay I -O the rapy; consider hospi[INVESTIGATOR_059]
•Rule out alternative causes (myocardial ischemia, 
viral infection, nutritional deficiency, thyroid, etc)
•Prompt cardiology consultat ion for any  cardiac 
signs and/or symptoms, evaluation may include:
•EKG  ± continuous cardiac monitoring
•Echocardiogram
•Troponin and CPK monitoring
•In absence of cardiac signs and/or symptoms:
•Monitor CPK and renal function
•Consider EKG and troponin monitor ing
•Up to 2 mg/kg/day methylprednisolone IV or oral 
equivalent
•Consider prophylactic antibiotics for opportunistic 
infections•If improves to grade [ADDRESS_229682] 1 month
•Retreatment may be 
considered after resolution to 
baseline and completion of 
steroid taper
•If no improvement observed , 
treat as Grade 3 -4 
Revised Protocol No.: 02
Date: 02-Aug-2017 128
3.0
Approved
930107718
3.0
v
Clinical Protocol CA209800
BMS -936558 nivolumab
Grade 3 :
Severe with symptoms at rest or 
with minimal activity or exertion 
(myocarditis)
Pain associated with severe 
weakness; limitin g self care 
activities of daily living (myositis)
Grade 4 :
Life Threatening; urgent 
interventio n indicated (e.g., 
continuous IV therapy or 
mechanical hemodynamic support)•Permanently discontinue I -O therapy; hospi[INVESTIGATOR_18552] 
•Rule out alternative causes (myocardial ischemia, 
viral infection, nutritional deficiency, thyroid, etc)
•Urgent cardiology consultation for any cardiac 
signs and/or symptoms, evaluation may include:
•EKG  ± continuous cardiac monitoring
•Echocardiogram
•Tropo nin and CPK monitoring
•Consider Cardiac MRI and myocardial 
biopsy
•In absence of cardiac signs and/or symptoms:
•Monitor CPK and renal function
•Consider EKG and troponin monitoring
•2-4 mg/kg/day methylprednisolone IV or 1 g IV 
bolus 
•Add prophylactic antibio tics for opportunistic 
infections•If improves to grade [ADDRESS_229683] 6 weeks
•If no improvement , consider 
additional 
immunosuppressants
*Patients with clinical signs or symptoms of rhabdomyolysis should be evaluated for myositis/myocarditis per the recommendations in this algorithm.
Revised Protocol No.: 02
Date: 02-Aug-2017 129
3.0
Approved
930107718
3.0
v